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ABSTRACT
Human acidic fibroblast growth factor (aFGF/hFGF-1) is one of the promising molecules
to be investigated to generate an in-depth understanding of the pathological mechanism of
Alzheimer's disease (AD) neurodegenerative disorder characterized by the presence of amyloid
fibrils. Some in vivo and human brain tissue studies proved the correlation of high-level
expression of FGF-1-induced neuroinflammation and the occurrence of AD. The presence of
amyloid fibrils as a hallmark of AD can be related to the generic property of the proteins to form
amyloid fibrils; High level of FGF-1, in this case, may contribute to the formation of amyloid
fibrils. As a heparin-binding protein, hFGF-1 requires heparin to bind in the heparin-binding
pocket to provide protection from proteolysis and heat inactivation and potentiate the mitogenic
activity of FGF-1. Due to the importance of heparin-binding pocket to the native structural
stability of the FGF-1, we hypothesized that destabilization of heparin-binding pocket might
facilitate amyloid fibrils formation in FGF-1.
We carried out in vitro studies by using sodium dodecyl sulfate (SDS) as an amyloid
fibril inducer and sucrose octasulfate (SOS) to mimic the activity of heparin to prove our
hypothesis. Our study can be a preliminary step to understand the significant role of heparinbinding pocket in amyloid fibrils formation and explore its potential as a druggable site in search
of the cure of AD. Fluorescence spectroscopy, limited trypsin digestion, transmission electron
microscopy, and mass spectrometry were performed to achieve the objective of this research
project. The results of this study suggest that 0.2mM is the optimum concentration of SDS to
induce amyloid-like fibrils formation in hFGF-1 (wild-type FGF-1). The presence of SOS is
found to protect hFGF-1 from fibrillation induced by SDS, reduce, and disaggregate fibrils

formation in hFGF-1. Stabilization of the heparin-binding pocket renders the ability of hFGF-1
to protect and reduce the chance of amyloid fibrils formation.
Keywords: Alzheimer's disease, amyloid-fibrils, FGF-1, sodium dodecyl sulfate (SDS),
sucrose octa sulfate (SOS), heparin-binding pocket.
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CHAPTER 1
INTRODUCTION
Accumulation of aggregated intracellular and extracellular protein is a major pathological
hallmark of neurodegeneration associated with misfolded proteins such as Alzheimer's disease
(AD), Parkinson's disease (PD), and Huntington's disease (HD)1, 2. The prevalence of these
highly debilitating diseases fuels extensive research in the field of protein aggregation as a part
of the relentless pursuit of the cure of the diseases.
Regarding its structural features, there are two different types of protein aggregates:
amyloid fibrils and amorphous aggregates. Amorphous aggregates comprise mostly disordered
polypeptide chains, despite its molecular assembly containing high content of β-sheet structure in
particular regions. Amyloid fibrils are highly ordered and repetitive structures that share
common features, such as canonical cross-β structure and the frequent presence of repetitive
hydrophobic or polar interactions along the fibrillar axis. All polypeptides, regardless of its
sequence, display the similar fold and share common morphologies (long, unbranched, and often
twisted structures a few nanometres in diameter)1-3.
It is suggested that polypeptide chains' capability to adopt amyloid-like conformations is
a fundamental feature of polypeptide chains; however, the tendency of the structure formation cis
significantly varied with the sequence. The reaction rate of the amyloid fibrillogenesis is
concentration-dependent and can increase by the addition of homologous pre-aggregated
polypeptides that perform as seeds/templates1-3.
One of the notorious diseases inflicting the aging population associated with the amyloid
fibrils (amyloid-β) is Alzheimer's disease. Alzheimer's disease is related to the alteration of the
brain biochemical environment, accumulation of both protein fragment amyloid-β (Aβ) outside
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neurons, and an abnormal form of the protein tau (tau tangles) inside neurons, are two of several
brain changes related to Alzheimer's disease. There are 5.8 million people in the United States
who have Alzheimer's disease. This number is predicted to increase to almost fourteen million by
2050. The national economic burden in 2019 because of Alzheimer's and other dementia is two
hundred ninety billion dollars. These costs could increase in the future (2019 Alzheimer's
Disease Facts and Figures, 2019). In the past twenty years, most of the drugs under trial, e.g.,
Crenezumab, Gantenerumab, Solanezumab, and Bapineuzumab) for AD have focused on
tackling Aβ peptide accumulation; the majority of Alzheimer's drugs development based on the
concept of debatable amyloid cascade hypothesis.
Nevertheless, most of the drugs could not produce clinically beneficial results 4.
Surprisingly, Aducanumab, the drug that is decreasing the size of amyloid-β plaque 4 and its
phase III trial was halted in March 2019 made its reversal in October 2019. It shows that
amyloid-β is still a relevant drug target. More research devoted to unraveling the molecular
mechanism of AD should pursue to aid acceleration in the field of Alzheimer's drug
development.
Human acidic fibroblast growth factor (aFGF-1 or FGF-1) is one of the promising
molecules to be explored to gain an in-depth understanding of Alzheimer's disease. This growth
factor originates from neural tissue, where it is found to be highly concentrated. The proliferation
and differentiation of various cell types in vitro are affected by FGF-1. FGF-1 activates the
neuron survival mechanism. It is delivered from the ependymal cells of the cerebral third
ventricle into the cerebrospinal fluid (CSF)5, 6. FGF-1 is a heparin-binding protein; heparin
renders protection from proteolysis (trypsin digestion) and heat inactivation and potentiates the
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mitogenic activity of FGF-17. Under oxidizing conditions, binding to heparin increases FGF
stability8.
Some previous studies link the presence of a high level of FGF-1 and the occurrence of
Alzheimer's disease5, 6, 9, 10. FGF-1 may play a significant role in AD not only because of its
potency in mediating neuroinflammation but also the property of FGF-1 as polypeptide chains to
form amyloid-like conformations that the concentration of the protein itself can influence its
reaction rate. In addition to that, human FGF-1 tends to unfold at physiological temperature in
the absence of sugar poly anions11, 12.
Therefore, exploring the role of destabilization of heparin-binding pocket in amyloid
fibrils formation can lead to an understanding of the mechanism of amyloid fibrils formation in
FGF-1. Subsequently, we can also obtain more in-depth knowledge of the role of heparinbinding pocket in protein aggregation, especially for the heparin-binding protein family.
Presumably, it also provides a novel drug target to prevent protein aggregation that can aid future
research in exploring a new avenue of Alzheimer's drug development.
1. Protein Folding, Misfolding, and Aggregation
Endoplasmic reticulum (ER) is an organelle that is specialized for protein folding13. In this
compartment, proper protein folding of a newly synthesized polypeptide is achieved through the
interaction with the molecular chaperones and folding enzymes (such as protein disulfide
isomerase and prolyl peptidyl cis-trans isomerases)13. Molecular chaperones are proteins that assist
other proteins in accomplishing their native active conformation but are not part of the final protein
structure14. ER contains two major chaperones system: the classical chaperones (such as Hsp70
and Hsp90 families) and the carbohydrate-binding chaperone system (lectin chaperones)13. Protein
disulfide isomerase (PDI) is the most abundant foldase and best-characterized oxidoreductase in
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ER15. Oxidoreductase plays a critical role in achieving a decent rate of protein folding, otherwise
ample aggregation and degradation will occur13. Prolyl peptidyl cis-trans isomerases (PPIases) is
a folding enzyme that catalyzes the isomerization between the cis and trans forms of peptide
bonds13.
Trafficking of the protein from the ER and its degradation via endoplasmic reticulumassociated degradation (ERAD) is closely related to the folding of the protein in the ER16. The
faith of the protein after the entry to the ER is the formation of folding intermediates16. Some of
these folding intermediates fold properly, and others are targeted for degradation16. The proteins
that fold correctly will exit the ER16. Whereas, the intermediates that do not fold correctly will be
hampered from secretion by their aggregation or interaction with ER folding factors, or by a
combination of the two16.
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Figure 1 Co- and post-translational protein folding in the lumen of the Endoplasmic
Reticulum
Top panel, the ribosome (grey), sits on the Sec61 translocon (orange) to support cotranslational
translocation of the nascent chain into the ER lumen. The oligosaccharyltransferase (OST)
attaches preassembled glycans (tree structure) to Asn on the nascent chain. BiP (green) and PDI
(purple) are positioned for early assistance. Disulfide bonds start to form. The signal sequence
peptidase complex (SPC, light blue) cleaves the amino-terminal signal sequence. Glucosidase I
(GIsI) removes the terminal glucose residue (orange triangle) from the N-linked glycan. The
diglucosylated glycan can bind to the membrane-associated lectin, malectin (dark blue).
Glucosidase II (GIsII) removes second glucose to generate a monoglucosylated glycan structure
that is bound to calnexin (CNX, green), a lectin chaperone associated with the oxidoreductase
ERp57 (pink). Lectin chaperone binding continues until GIsII removes the final glucose
residue13.
Bottom panel, the listed factors interact co- and posttranslationally, after the nascent chain's
translation has been completed. These factors help with maturation and the sorting of the native
or nonnative protein for its various fates13.
2. Alzheimer's Disease
Amyloid β peptide (Aβ) and tau protein have an important role in the occurrence of
Alzheimer's disease (AD). Two different features marked the brains of AD patients: (1) formation
of the extracellular amyloid plaques from the amyloid plaques formed by the proteolytic product
(Aβ) of the amyloid precursor protein (APP), a cell surface receptor processed by β-secretase (βamyloid cleavage enzyme, BACE1) and γ-secretase; (2) formation of neurofibrillary tangles
5

(NFTs) by hyperphosphorylated forms of the neuronal microtubule-associated protein tau 17. Even
though neuronal toxicity in AD is correlated to Aβ and tau; it remains vague which molecular
interplay occurs between these two proteins1.
α-secretase process APP in a healthy brain via non-amyloidogenic pathway, resulting in a
secreted fragment and a C-terminal part, which is subsequently cleaved by γ-secretase into smaller
peptides. The cell will remove these smaller peptides eventually. Meanwhile, in the amyloidogenic
pathway, APP cleavage is processed by β-secretase, and afterward, γ-secretase action will produce
Aβ peptide17.
Metal ions play roles in AD, and it showed by the evidence that APP processing can be
shifted towards the amyloid pathway in the presence of metal ions. It is also found that a high
concentration of trace metals exists in amyloid plaques. α-secretase activity is affected by Zn2+ and
Fe2+/3+, while β-secretase activity is influenced by the Cu2+ 18. Aβ is found to be phosphorylated in
vivo that is linked to the increase in toxicity. Therefore, trace metals, Fe presumably a pivotal
player in the Aβ aggregation pathway because the phosphate group considerably increases the
peptide ability to bind Fe1, 19. This finding supports other evidence that showed Fe impedes the
turnover of toxic oligomeric Aβ metastable species into ordered fibrils20. Furthermore, it is known
that binding of Aβ to oxidized forms of Fe or Zn2+ generates hydrogen peroxide that could involve
in the general toxicity initiated by APP misprocessing21. In healthy conditions, Aβ is localized in
the interstitial fluid of the brain, but AD amyloid plaques are found in particular brain areas, which
turn out to be the most compromised/affected by the disease 1.
3. The structure of amyloid fibrils
The modern biophysical definition of amyloid fibrils is an unbranched protein fiber whose
repeating substructure contains β strands that run perpendicular to the fiber axis, creating a cross-

6

β sheet of indeterminate/indefinite length. Therefore, an ordered arrangement of many (usually
thousands) copies of a peptide or protein is constituent of amyloids22. Electron microscopy (EM)
analysis shows that amyloids exhibit long, nonbranched filaments with diameters 6-12 nm22.
Characteristic of X-ray fiber diffraction patterns is found in amyloid structure due to the repeating
cross-β sheet motif22. Frequently, fibrils contain multiple protofilaments twisted around the fibril
axis 1, 2.
X-ray fiber diffraction revealed that amyloid fibrils generate extended β-sheets stabilized
fundamentally by intermolecular hydrogen bonds entailing mainly back-bone atoms running
parallel to the axis of the fibril in a structure defined as cross-β23. Moreover, it found that one face
of these extended β-sheets contains exposure to water. In contrast, the other one is tightly packed
against another such β-sheet with a dry interface stabilized by van der Waals and hydrophobic
interactions between interdigitated side chains 23.
In contrast with the conventional protein structures, amyloid fibrils exhibit the polymorphic
characteristic. Determined by the environmental condition of the incubation of the monomeric
protein, such as ionic strength, pH, temperature, concentration, type, and degree of stirring of the
aggregating solution, different amyloid morphologies can be generated. This property of amyloid
fibrils implies that the dependent factor of the structural features of the fibrils formed by a
particular protein can be related to the milieu where amyloid formation takes place23.
4. Molecular mechanisms of fibril formation
Amyloidogenesis is a biochemical process that converts a soluble and innocuous/native
protein into insoluble and fibrillar protein aggregates, called amyloid fibrils 24. It is suggested that
the capability of polypeptide chains to adopt amyloid-like conformations is a fundamental feature
of polypeptide chains; however, the tendency of the structure formation is significantly varied with
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the sequence. The reaction rate of the amyloid fibrillogenesis is concentration-dependent and can
increase by the addition of homologous pre-aggregated polypeptides that perform as
seeds/templates1-3.
The dependent factor of the reaction rate of the amyloid fibrillogenesis is the protein
concentration. This process can be hastened by the incorporation of homologous pre-aggregated
polypeptides, acting as seeds/templates. Interaction between the monomers — acting as 'active'
growing unit — and the templates will promote the monomers' structural transformation to the
amyloidogenic conformation. There are two models of amyloid fibrillogenesis: nucleationelongation polymerization and double-concerted fibrillation1, 2, 24, 25. Based on the nucleationelongation

polymerization

model,

there

are

three

main

steps

of

amyloid

fibril

formation/aggregation1:
1. The lag phase is a thermodynamically unfavorable reaction of nuclei formation. It occurs
through the association of soluble species (usually monomers) where prolonged incubation
of the amyloidogenic proteins is necessary. Overall, the kinetics of the amyloid reaction is
affected by the formation of the nuclei (rate-determining step). The lag phase involves
transformation steps from the soluble, native structure of the protein to the generation of
the first species exhibiting β-sheet conformation, subsequently forming nucleus as a
template. Pre-existing aggregates can act as a catalyst of the nucleation step. The initiation
of globular protein aggregation requires the thermodynamic destabilization of the native
monomer. In protein exhibiting a quarternary native structure, the functional oligomer
dissociation into monomeric subunits is required1.
2. Exponential phase, monomeric proteins coalesce to the template through conformational
transition, immediately after the nucleus (seed) is formed. Conformational transition cause
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polymerization and fibril growth in this stage. There are some different mechanism
responsible for the increase in structural order found at this stage: initially ordered β-sheet
oligomers cause the direct growth of fibrils, before fibril formation and elongation, the
transformation of these oligomers into β-sheet enriched non-fibrillar assemblies occur or
formation of large amorphous aggregates from initially disordered oligomers and
subsequent structural reorganization, first to nonfibrillar β-sheet rich assemblies and
eventually to fibrils1.
3. The stationary phase (under supersaturated condition) is a condition in which no more
association of soluble species to the ends of preformed fibrils. Furthermore, it includes
deceleration of the growth phase lead to the saturation phase and eventually fibril
maturation1.

Figure 2 Cartoon depiction of the kinetics of amyloid formation26
A partial destabilization of the native state is required in amyloidogenesis. The formation of
amyloid fibril is a nucleation dependent manner. It consists of three steps: lag or nucleation
phase, elongation or exponential phase, and stationary phase or saturation phase26
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Regarding the double-concerted fibrillation model, two consecutive, concerted
associations of monomers are required to form amyloid fibrils. Associations of the monomers will
subsequently generate oligomeric granular species that perform its function as a growing unit for
the fibril formation, in the absence of template24. The major driving force for the supra structures
formation is structural rearrangement within the oligomeric species. The final fibril is generated
through the interactions switch from intra-oligomeric to inter-oligomeric interactions since the
oligomers already consisted of interactive regions between constituting monomers 24.
5. Inhibitors of Amyloid Fibril formation
There are four class of well-documented amyloid fibril inhibitors (drugs and nutraceuticals)
used in the status quo or under investigation: anthracyclines and tetracyclines, sterols, peptide and
engineered antibodies, polyphenols, and nanoparticles27.
Anthracyclines and tetracyclines
4'-iodo-4' deoxydoxorubicin (IDOX), the anthracyclines anticancer drug is found to
generate clinical benefits in five patients who suffered from immunoglobulin light-chain
amyloidosis by inhibiting the progression of amyloidosis28. Moreover, in vitro studies showed that
IDOX was able to strongly bind to five natural amyloid fibrils but native amyloid precursor28.
However, the cardiotoxicity effect of IDOX requires a structurally similar agent with a better
toxicological profile28. The similarity of the structure between the polycyclic conjugated structure
of tetracyclines (TCs) and the aglycone moiety of IDOX combined with the clinical benefits and
well-characterized pharmacological, pharmacokinetic, and toxicological profile made it a proper
candidate to replace IDOX28. A positive result of TCs' fibrillogenesis inhibitory effect on human
prion protein (PrP), human amylin (IAPP), huntingtin, W7FW14F, apomyoglobin, poly-(A)
binding protein nuclear 1, α-synuclein, β2M, and immunoglobulin light chain (LC) was obtained
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from the in vitro and in vivo studies28. To date, no clear data is available to explain the relationship
between the structures of TCs and their anti-amyloidogenic activity28. Information derived from
molecular mechanics investigation demonstrated that the observed activity on TCs was linked to
the flexibility between the extended and folded conformations of TCs28.
Sterols
Sterols such as squalamine and its derivative, trodusquemine show the ability to prevent
the aggregation of the protein α-syn29, 30. Protein α-syn can form deposits known as Lewy bodies,
a hallmark of Parkinson's disease (PD)29. Both squalamine and trodusquemine can displace α-syn
monomers from the membranes required for the aggregation of the α-syn29, 30. Furthermore,
trodusquemine also shows an inhibitory effect on the secondary nucleation of aggregation through
direct interaction with α-syn27, 29, 30.
Small peptides, also known as β-breakers are soluble short sequence portions of
amyloidogenic proteins. Administration of β-breakers prevents the formation of protein
aggregation or promoting the disaggregation of existing fibrils. A positive result was gained from
an in vitro study regarding the effect of small peptides on Aβ. Despite some drawbacks of the small
peptides such as poor stability, susceptibility to proteolytic degradation, and short half-life,
attempts have been made to overcome these challenges through chemical modification such as Nmethylation and cyclization 31-35.
Peptides and Engineered Antibodies
To date, a recombinant human IgG1 antibody, Aducanumab, showed the most favorable
result in which it showed the decline of brain amyloid burden coupled with a positive effect on
cognition and global clinical status, with dose-dependent trends4. Aducanumab binds to soluble
Aβ aggregates and insoluble fibrils with more than 10,000-fold selectivity over monomers4.
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Figure 3 Cellular targets for anti-Aβ drugs
Anti-amyloid-β (Aβ) drugs in phase III clinical development for the treatment of
Alzheimer's disease and their mechanisms of action. AICD, amyloid precursor protein
intracellular domain; BACE, β-secretase; sAPPβ, soluble amyloid precursor protein-β4.
Polyphenols
Polyphenols are well-known for the antioxidant property. Moreover, they also render the
inhibitory effect of amyloid aggregation27. Epigallocatechin-gallate (EGCG), the major catechin
found in the leaves of green tea, demonstrates its activity to inhibit the formation of aggregates
from several potentially amyloidogenic proteins or peptides, such as Aβ, α-syn36, IAPP37,
huntingtin38, ATX339. EGCG form interaction with both monomeric protein and oligomeric
aggregates. EGCG mechanism of action is affected by the difference in protein target38,

40

.

Generally, EGCG can redirect the aggregation towards off-pathway, non-toxic, β-sheet-poor
aggregates, and/or remodeling the aggregates after their formation38, 40. Polyphenols commonly
found in grapes, berries, red wine, resveratrol demonstrates a well-characterized effect on Aβ
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amyloid aggregation27, 41. It can retard fibril formation and disaggregate preformed fibrils but not
inhibiting oligomer formation27. Curcumin exhibits its capability to prevent oligomerization in Aβ
and tau27, 42, 43, redirect the aggregation towards non-toxic oligomers (Aβ and α-syn)27, 44, 45, and
disaggregate preformed fibrils (Aβ, tau, and α-syn)27, 42, 43, 45. Oleuropein — the main phenolic
compound of olive oil — possesses the capability to inhibit the formation of toxic amyloid
aggregates27. Predominantly, it can redirect the aggregation towards non-toxic, off- pathways.
Moreover, oleuropein also thwarts protein binding to the plasma membrane27.
Nanoparticles
Nanoparticles exhibit potency to inhibit amyloid aggregation27. According to their
composition, nanoparticles possess a particular degree of specificity towards amyloid deposit27.
For example, polytrehalose nanoparticles demonstrate their potential to inhibit the aggregation of
poly-Q proteins46. Gold nanoparticles effectively inhibit aggregation of insulin47, and Aβ48 and
silver and iron oxide nanoparticles can hinder the aggregation of amylin49. Furthermore, their
ability to cross the blood-brain barrier at low concentration is a benefit of nanoparticles as an
inhibitor of amyloid aggregation27.
6. Fibroblast Growth Factors Family
Growth factors play an important role in regulating cellular functions, including adhesion,
proliferation, migration, and differentiation in the epithelium, bone, and soft connective tissue50.
A wide array of biological functions such as cellular proliferation, survival, migration, and
differentiation are modulated by fibroblast growth factors (FGFs) that signal through FGF
receptors (FGFRs)50. There are 23 members of the FGF family with only 18 FGFR ligands; four
family members are FGF homologous factors (FGF-11, FGF-12, FGF-13, and FGF-14), which do
not bind with FGFR51. Phylogenetic analysis reveals that there are seven subfamilies of the human
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FGF gene family: FGF-1, FGF4, FGF7, FGF8, FGF9, FGF-11, and FGF-19 (Figure 4)52. FGF-1
and 2; FGF4, 5, and 6; FGF 3, 7, 10, and 22; FGF8, 17, and 18; FGF9, 16, and 20; FGF-11, 12,
13, and 14; and FGF-19, 21, and 23 are clustered as the FGF-1, FGF4, FGF7, FGF8, FGF9, FGF11, and FGF-19 subfamily, respectively52. In vertebrates, the variation of the molecular weight of
FGFs is found from 17-34kDa, while the FGF in Drosophila is 84kDa53. Sequence identity of 16%65% is shown by all members of the family that share a conserved sequence of 120 amino acids53.
Acidic fibroblast growth factor (aFGF/FGF-1) and basic fibroblast growth factor (bFGF/FGF-2)
are the two best-characterized members of the FGFs family54. FGF-1 and FGF-2 show 55%
sequence identity with a different isoelectric point, 5-6 and 9.6, respectively54. Moreover, the two
FGFs can be distinguished by the necessity of FGF-1 to bind heparin to stimulate its mitogenic
activity, unlike FGF-2 that does not require binding to heparin54.
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Figure 4 Phylogenetic tree of human FGF family52
The Human FGF gene family consists of seven subfamilies containing two until four members
for each subfamily. The lengths of the branch are proportional to the evolutionary distance
between each gene50
.

7. Fibroblast Growth Factors Signaling Pathway
The pathway of FGFs metabolism is mediated by the association of FGFs with a specific
tyrosine kinase receptor (FGFR) and heparin sulfate proteoglycans (HSPG) to assemble a ternary
complex on the cell surface. Ligand binding causes FGFRs to undergo a dimerization process that
causes tyrosine autophosphorylation55. These phosphorylated tyrosines perform their function as
high-affinity binding sites for proteins containing Src-homology 2 (SH2) domains or
phosphotyrosine binding (PTB)55. Binding of these intracellular proteins and phosphorylated
tyrosines initiates several signaling pathways (e.g., RAS/MAP Kinase pathway, PI3 Kinase/AKT
pathway, and PLCγ pathway) that leads to specific cellular responses50,

55

. The membrane-

associated docking protein, fibroblast growth factor receptor substrate 2 (FRS2) binds to the FGFR
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juxtamembrane domain through its PTB domain and undergoes phosphorylation by the receptor55.
A variety of adaptor proteins — growth factor receptor-bound protein 2 (Grb2), the guanine
nucleotide exchange factor Son of sevenless (Sos) — are recruited by the FRS255. G-protein Ras
is then activated by the recruitment of these adaptor proteins, which leads to the stimulation of the
mitogen-activated protein kinase (MAPK) pathway55. The MAPK pathway outcomes are DNA
synthesis, proliferation, and/or differentiation that vary depending on the cell type or state. FRS2
signaling complex also causes activation of PI3 (phosphoinositide 3) kinase/AKT pathway, which
leads to cell survival (Figure 3)55. FGF-1 exhibits a unique feature among the FGF family through
its ability to stimulate all FGFRs. As a result, FGF-1 is a broad specificity human mitogen that is
designated/entitled as "universal FGFR ligand." Plasticity in the N terminus region plays an
essential role in its broad specificity56-58.
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Figure 5 FGFs signaling pathway50
FGFs promote the stimulation of tyrosine phosphorylation of the docking protein FRS. This
process is followed by the formation of GRB2-SHP2-GAB-1 complex resulting in activation
of RAS-MAP kinase pathway and PI3 kinase/AKT pathway. In another pathway, PLCγ
pathway, phosphatidylinositol is hydrolyzed by the activated PLCγ, generating IP3 and DAG
and results in PKC activation. FRS2: fibroblast growth factor receptor substrate 2, GRB:
guanine nucleotide exchange factor, SOS: son of sevenless, RAS: monomeric G-protein,
RAF: kinase, MEK: kinase, MKP1: MAP kinase phosphatase, PIP2: phosphatidylinositol
(4,5)-biphosphate, IP3: inositol triphosphate, DAG: diacylglycerol, PKC: protein kinase C50

8. Structure of the human fibroblast growth factor
FGF-1 is identified by the pseudo-threefold rotational symmetry as a member of the βtrefoil family of proteins59, 60. The overall structure of FGF-1 contains three repeating "trefoil-fold"
structural motifs61. Each motif is around 42 amino acids (with some variation in length between
the three motifs)61. Each motif comprises four β-strands: two β-strands of each motif involve in
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the overall six-stranded β-barrel architecture, and two β-strands of each motif contain a β-hairpin61.
The three β-hairpins create a triangular arrangement that packs against the bottom of the β-barrel61.
The x-ray crystal structure of human FGF-1/hFGF-1 (the mature 140 amino acid form) with 2.0 Å
resolution (PDB ID: 2AFG) has been established (Figure 6)12. The general arrangement of the
primary and secondary structure is displayed in Figure 561. The predominant native structure of
FGF-1 is β-sheet that contains eight tyrosine, one tryptophan, and three cysteine residues61. Unlike
other extracellular proteins that contain cysteine residues forming disulfide bonds; Only free
cysteine residues are found in FGF-161. Furthermore, in native FGF-1, seven of eight tyrosine
residues are exposed to the solvent, whereas the single tryptophan shows a partial solvent
accessibility59-61.

(a)

(b)

Figure 6 Ribbon Diagram of Human FGF-1 (hFGF-1) (PDB ID 2AFG) and Structure of
Human FGF-1 in the region of residues Asn 18, Lys 113, and Lys 118.
Structure of human FGF-1 depicted as a ribbon diagram. The ribbon diagram shows that hFGF1 interacts with a sulfate ion (a). The sulfate ion interacts mainly with the Nδ2 atom of Asn 18,
the main chain amide of Lys 113, and the Nζ atom of Lys 118 (b)12.
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Figure 7 Structure of a human FGF-1 monomer complexed to a hexasaccharide heparinanalogue62
The amino acids sequence of the monomeric FGF-1 is
NLPPGNYKKPKLLYCSNGGHFLRILPDGTVDGTRDRSDQHIQLQLSAESVGEVYIKST
ETGQYLAMDTDGLLYGSQTPNEECLFLERLEENHYNTYISKKHAEKNWFVGLKKNGS
CKRGPRTHYGQKAILFLPLPVSSD
9. The Heparin-binding affinity of the human acidic Fibroblast Growth Factor (hFGF1)
Heparin-binding capacity is one of the essential physical properties of FGFs. The study has
revealed that heparin comprising of at least four monosaccharide units is mandatory to stabilize
FGF-1 from thermal unfolding61. Upon binding with heparin, FGFs are unsusceptible to
denaturation by acid or heat and proteases such as thrombin, trypsin, plasmin, subtilisin, papain,
and thermolysin54, 63. Crystallographic studies have shown that interaction between a high negative
charge density HS with positively charged amino acids in the N-terminus (residue 18) and Cterminus region (residues 112-128) exist64, 65. Another crystal structure (PDB ID: 1E0O) shown
that the C-terminal region of FGF-1 is a dominant heparin-binding site. Seven residues of FGF-1:
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K126, K127, N128, K132, R133, R136, and K142 promote heparin-binding in this crystal
structure64. This study also revealed that van der Waals has a significant contribution to the binding
of heparin and FGF-164.
Binding of heparin analog to FGF-1 causes an overall reduction in flexibility of FGF-1
(except for a few residues), as revealed by NMR studies. Nevertheless, the flexibility of FGF-1 in
strand 12 was not considerably altered by the heparin-binding due to the presence of Leu133 and
Leu135, residues located in the receptor-binding regions of FGF-161. The unaffected flexibility of
the amino acid residues that are responsible for the receptor binding of FGF-1 may contribute to
the broad-specificity of FGF-1 towards FGFRs61. Another study revealed that residue K132,
located in the base of the pocket toward the protein core, contribute to form interaction with critical
N-sulfate and 2 O-sulfate groups on the heparin iduronic acid sugar66.

Figure 8 Complex of the FGF-1-FGFR2-Heparin64
The heparin is drawn as a stick model. Regions of positive charge are represented in blue that
surrounds the heparin decasaccharide64.
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Figure 9 Complex of Heparin-FGF-1 generated by Pymol65
Dimer of FGF-1 is linked by heparin. FGF-1 dimer is drawn as a green cartoon model and
heparin is represented as a stick model. The heparin-binding pocket of FGF-1 is represented in
magenta with sequence GSNWFVGLKKNGSCKRGPRTHYGQK: PDB ID: 2AXM65.

10. Interaction of SOS and Heparin-Binding Pocket
Sucrose octasulfate (SOS), low-molecular-weight sulfated sugar is capable of binding and
stabilizing FGFs11. Therefore, it is deemed to stimulate fibroblast growth factor (FGF) signaling11.
Previous studies have shown that SOS imitates heparin action in supporting FGF-induced
neoangiogenesis and cell proliferation in vitro11. Extending the half-life of FGF is suggested as the
mechanism in which SOS strengthens FGF signaling. Upon binding to SOS, FGFs are protected
against high temperatures and low pH11.
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Figure 10 Structure of Heparin Disaccharide (a) and ucrose Octasulfate (b)67
SOS, heparin, and other proteoglycans have the same binding site. The crystal structure of
a 1:1 complex between FGF-1 and SOS at 2.7Å resolution showed that SOS binds to a positively
charged region of FGF-167. This region contains residues 112-127 where SOS mainly interacts
with Lys112, Arg116, Lys118, and Arg12267. Moreover, this region is also crucial for heparinbinding site. Binding of SOS and FGF-1 allows the neutralization of several positively charged
residues that can destabilize the native structure of FGF-1 by electrostatic repulsion67.

Figure 11 Schematic Representation of SOS binding to FGF-167

11. Plausible role of the Fibroblast Growth Factors in Amyloid Diseases
Acidic fibroblast growth factor (aFGF-1 or FGF-1) is one of the promising molecules to
be explored to gain an in-depth understanding of Alzheimer's disease. The origin of this growth
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factor is from neural tissue, where it is found to be highly concentrated5. The proliferation and
differentiation of various cell types in vitro are affected by FGF-1. FGF-1 activates the neuron
survival mechanism. It is delivered from the cerebral third ventricle's ependymal cells into the
cerebrospinal fluid (CSF) 5, 6.
Some previous studies link the presence of high levels of FGF-1 and the occurrence of
Alzheimer's disease. The first study observed that astrocytes containing high levels of FGF-1
presented around senile plaques in seven Alzheimer's patients' postmortem brain tissue6. The
examination was conducted by immunohistochemistry employing a specific antiserum against
FGF-16. The diagnosis of Alzheimer's disease was established in every case by the presence of a
large amount of plaques and tangles6. The promoting factor of the astrocytes assembly around the
plaques was presumed due to the high binding affinity between FGF-1 and heparan sulfate
proteoglycan6. This presumption is strengthened by the fact that the mitogenic activity of FGF-1
is increased more than 100-fold by heparin and heparin sulfate 6.
The result from in vivo observation showed that high levels of secreted FGF-1 upregulated
apolipoprotein E (apoE) production in astrocytes of the brain injury lesion by autocrine
mechanism9. Therefore, it was presumed that stress conditions (e.g., heat shock, oxidation, and
long-term culture) trigger astrocytes to generate FGF-1 to induce the production of apoE-HDL
(apolipoprotein E-high-density lipoproteins), an important compound for the healing process in
the postinjury brain9. ApoE synthesis is triggered by FGF-1 via the PI3K/Akt (phosphoinositide
3-kinases/ protein kinase B) pathway rather than Ras/MEK/Erk (mitogen-activated protein kinase
kinase/ extracellular signal-regulated kinase) pathway 9.
Another study found that the level of FGF-1 in the cerebrospinal fluid and serum of thirtytwo Alzheimer's patients were higher than those thirty-two patients without Alzheimer's disease
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(normal controls)5. Western blotting and enzyme-linked immunosorbent assay (ELISA) was
carried out to measure the level of the FGF-15. This study was based on the fact that FGF-1 is one
of the most pivotal central nervous system (CNS) growth factors and a powerful mitogen5.
Moreover, it was assumed that biochemical brain abnormalities could be manifested in
cerebrospinal fluid (CSF) because of CSF proximity to the extracellular space of the brain 5. It was
found that FGF-1 plays an essential role in enhancing microglial and astrocyte-mediated
neuroinflammation10. Neuroinflammation, the hallmark of Alzheimer's disease progression, can
be a potential drug target in Alzheimer's drug development10. It can be pursued by blocking the
expression and release of FGF-1 because inhibition of FGF-1 can prevent the expression of
neuroinflammatory molecules10.
It can be concluded from these in vivo and human brain tissue studies that astrocytes
express a high level of FGF-1 that leads to apoE-HDL production in Alzheimer's disease;
astrocytes activity in enhancing FGF-1 production promotes neuroinflammation, a hallmark of
AD. FGF-1 may play a significant role in AD, not only because of its potency in mediating
neuroinflammation but also the property of a FGF-1 as polypetide chains to form amyloid-like
conformations. The reaction rate of amyloid formation can be influenced by the concentration of
the protein itself 1-3.
12. Methods for Assessing Amyloid Fibrils Formation
a) Transmission electron microscopy (TEM)
Fibrillar characteristic is showed by the amyloid fibrils when investigated under electron
microscope26. The TEM27 can analyze amyloid aggregates extracted from tissue or synthesized in
vitro while the non-fibrillar aggregates are lost during the extraction process and are not present in
in vitro experiments2628. Observation through TEM showed that amyloid aggregates possess a wavy
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or rod-like or twisted structure with a diameter ranging from 5-25 nm26. Information about the
variations of the degree of twisting, the number of protofilaments forming a fibril, and mature fibrils
diameter can be obtained from the TEM images26. Various TEM images showed that regardless of
their biochemical form, amyloid deposits from different tissue consist of a bundle of not branched,
straight fibrils, ranging from 6 nm to 13 nm in diameter (average 7.5-10 nm) and 100-1600 nm in
length 26.
Circular Dichroism (CD)
Circular dichroism (CD) is based on the distinctive absorption of left-handed and righthanded circularly polarized light of molecules in the absence of a magnetic field68. The difference
in absorbance for left-handed and right-handed circularly polarized light, ∆A (= AL – AR) is the
experimentally measured parameter in CD68. CD is an absorption phenomenon in which the
chromophores that produce the CD spectrum are precisely like those generating a conventional
absorption spectrum68. Either chirality of the chromophore or location of the chromophore in an
asymmetric environment must be fulfilled to exhibit a CD signal68. The asymmetry of the
polypeptide chain and the asymmetry at the α-carbon atoms in the amino acid residues are two
factors that cause the optical activity of proteins 68.
There are two types of protein circular dichroism (CD) spectroscopy: far UV or backbone with data collection using wavelength from 190 to 250 nm and near UV or aromatic with
data collection using wavelength from 250 to 300 nm 69. The near-UV CD bands of proteins (310255 nm) are generated by Trp, Tyr, Phe, and cystine 68, 69. Near-UV CD bands can be used to
derive information regarding the tertiary, and occasionally quaternary structure of the protein 68.
The far-UV CD bands of proteins can provide information regarding the secondary structure of
the protein (α-helix, β-sheet, β-turn, and unordered content)68.
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Circular dichroism provides a powerful qualitative characterization of the secondary
structure content of amyloid fibrils when the fibrils are soluble68. In general, the characteristic of
the far-UV spectra of different protein classes are68:
-

All-α proteins show an intense negative band with two peaks (at 208 and 222 nm) and a strong
positive band (at 191-193 nm)68. The intensities of these bands reflect α-helical content. ∆εmrw
values for a totally helical protein would be of the order of -11 M-1 cm-1 (at 208 and 222 nm)
and +21 M-1 cm-1 (at 191-193 nm)68.

-

The spectra of regular all-β proteins are significantly weaker than those of all-α proteins. These
spectra usually have a negative band (at 210-225 nm, ∆εmrw: -1 to -35 M-1 cm-1) and a stronger
positive band (at 190-200 nm, ∆εmrw: 2-6 M-1 cm-1)68.

-

Unordered peptides and denatured proteins generate a strong negative band (at 195-200 nm,
∆εmrw: -4 to -8M-1 cm-1) and a much weaker band (which can be either positive or negative)
between 215 and 230 nm (∆εmrw: +0.5 to -2.5 M-1 cm-1)68.
Fluorescence Spectroscopy
A molecule's ability to absorb a photon of appropriate energy promotes an electronic
transition from the ground state to an excited state70. To return to its ground state, a molecule in
an electronically excited state must emit the energy70. These processes are described by a Jablonski
diagram (Figure 12).
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Figure 12 Jablonski diagram
Illustration of the electronic levels of common organic molecules and possible transitions
between different singlet and triplet states70.
The absorption of a photon happens very rapidly (~ 10-15 sec) from the lowest vibrational
level of the ground state (S0) to the higher electronic and vibrational states (e.g., S1, S2)71.
Relaxation of the electron from higher energy states to the lowest vibrational level of the first
excited state (S1) occurs quickly (~10-10 sec to 10-12 sec); This phenomenon known as internal
conversion71. Radiative and nonradiative are two general pathways for the dissipation of excitedstate energy in the absence of photochemical reactions. Photon release occurs during the loss of
energy in a radiative pathway71. Fluorescence is the light liberated when the photon comes from
the first excited singlet state to the ground state71.
Moreover, an electron can move from the excited singlet state to an excited triplet state,
known as intersystem crossing71. Presumably, the release of a photon accompanies the return of
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the electron from the triplet state to the ground state71. The emission during this process is called
phosphorescence 71.
There are two types of protein fluorescence, intrinsic protein fluorescence and extrinsic
protein fluorescence. Intrinsic protein fluorescence relies on the signal from the naturally
fluorescent amino acid tryptophan and limitedly from tyrosine. While extrinsic fluorescence use
dyes that can form covalent and noncovalent bonding with the proteins72.
Tryptophan fluorescence is almost always associated with the term "natural protein
fluorescence" because it is the most highly fluorescent amino acid in proteins. Tyrosine is the
second most fluorescent amino acid in protein; Application of tyrosine fluorescence is mostly
limited to tryptophan-free proteins. Whereas, because of the weakness of phenylalanine
fluorescence, it is never used in protein studies72, 73.
The sensitivity of tryptophan emission to polarity and mobility of the environment makes
tryptophan fluorescence a pivotal tool in studies of protein structure and dynamics. Nearly all polar
protein groups can quench tryptophan fluorescence. There are some dynamic quenchers of
tryptophan fluorescence: aspartic and glutamic acid residues (effective dynamic quenchers in their
neutral form); lysine and arginine (are more effective in their charged forms); histidine; disulfide;
amide and peptide groups. At low pH, histidine shows its quenching effect through the formation
of a stacking complex with the indole ring. Even though single cysteine can be an effective
quencher, one of the strongest quenchers of tryptophan fluorescence is disulfide73.
Extrinsic fluorescent dyes, for example, Thioflavin T (ThT), Congo Red (CR) and 1anilino-8-naphthalenesulfonate (ANS) (Figure 3.) are used for the aim of protein characterization,
such as for aggregates characterization and identification, to monitor refolding and unfolding
processes, to examine amyloid fibril, molten globule intermediates, to access the degree of exposed
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surface hydrophobicity of the conformationally altered protein, etc. The interaction between the
dye and protein molecule could give alteration to the fluorescence emission through the alteration
of relaxation pathway which is the basic principle of the use of extrinsic dyes for protein
characterization74.
Interaction of ANS with protein molecules dictates ANS's fluorescence properties, which
result in alterations of polarity and viscosity of the environment72. The binding mechanism of ANS
to protein involves hydrophobic interactions, electrostatic interactions, and complementary
interactions such as van der Waals interactions72. In electrostatic interaction, the predominant
interaction is the ion-pairing between the negatively charged sulfonate groups of ANS with
positively charged amino acids, e.g., histidine, lysine, or arginine72.
ThT is among the most widely used dye to selectively stain and identify amyloid fibrils in
vivo and in vitro74. The result from the molecular dynamics simulations shows that ThT bind
parallel to the long axis of the fibril surface in grooves formed by side-chain ladders (Figure 13a
and 13b)74. ThT displays an additional absorption peak at 450 nm and becomes highly fluorescent
with an emission maximum at 480 nm74.
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Figure 13 (a) Cross-β structure of amyloid fibrils (b) ThT is proposed to bind along surface
side-chain grooves running parallel to the long axis of the β-sheet74.

AIMS OF THE STUDY
Some previous studies link the presence of a high level of FGF-1 and the occurrence of
Alzheimer's disease5, 6, 9, 10. FGF-1 may play a significant role in AD not only because of its
potency in mediating neuroinflammation but also the property of FGF-1 as polypeptide chains to
form amyloid-like conformations that the concentration of the protein itself1-3 can influence
reaction rate of the 1-3formation of amyloid-like structures1-3. In addition to that, human FGF-1
tends to unfold at physiological temperature in the absence of sugar poly anions11, 12.
Therefore, exploring the role of destabilization of heparin-binding pocket in amyloid
fibrils formation can lead to an understanding of the mechanism of amyloid fibrils formation in
FGF-1. Subsequently, we can also obtain more in-depth knowledge of the role of heparinbinding pocket in protein aggregation, especially for the heparin-binding protein family.
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Presumably, it also provides a novel drug target to prevent protein aggregation that can aid future
research in exploring a new avenue of Alzheimer's drug development.
In this project, we conducted some experiments using different techniques such as
fluorescence spectroscopy, limited trypsin digestion, transmission electron microscope (TEM),
and mass spectrometry to induce fibrils formation in hFGF-1, characterize the sodium dodecyl
sulphate (SDS)-induced fibrils formation in hFGF-1, and understand the molecular mechanism
of fibril formation in hFGF-1.
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CHAPTER 2
MATERIALS AND METHODS
1g of Ampicillin salt was dissolved in 10ml ethanol 50% to make a 0.1% Ampicillin
stock solution. The stock solution was stored at -20℃. 1M IPTG was prepared by dissolving
2.38g IPTG in 10ml distilled, di-ionized water (ddH2O). IPTG binds to and inactivates the lac
repressor. It leads to the activation of the lac operon and induction of protein expression. Three
sodium dodecyl sulphate (SDS) stock solutions were prepared: 10% (SDS-PAGE), 2mM
(Fluorescence Spectroscopy, Trypsin Digestion, Transmission Electron Microscopy, Mass
Spectrophotometry), and 15mM (Fluorescence Spectroscopy). 10%, 2mM, 15mM SDS were
prepared by dissolving 1g, 0.006g, and 0.043g SDS in 10ml ddH2O, respectively. 0.005g SOS
stock solution was dissolved in buffer pH 7.2 (10mM phosphate buffer + 100mM NaCl) to make
2mM SOS stock solution. The stock solution was stored at -20℃. Trypsin stock solution was
prepared by dissolving 3mg Bovine Trypsin in 1ml ddH2O. 8M Urea was prepared by dissolving
240.24g Urea in 500ml ddH2O. 1mg/ml ThT stock solution was prepared by dissolving 1mg ThT
in 1ml ddH2O .
1. Bacterial Transformation
1μl plasmid DNA (pET20b-pentaFGF-1 plasmid) was transformed into BL-21 (DE3)
pLysS competent E. coli cells. The incubation was conducted on ice for 30 minutes. The cells
were heat-shocked at 42℃ for 1 minute and immediately shifted to the ice for 3 minutes. 800μl
of sterile lysogen broth (LB) media was added to the cells inside the laminar hood. The mixture
was incubated in an orbital shaker at 37℃ for 45 minutes at 250rpm. 100μl of the mixture was
plated on separate labeled Ampicillin (Amp) Agar plates (containing 25μg/μl Amp) using sterile
steel spreader inside the laminar hood. The ampicillin (Amp) was used because FGF-1 plasmid
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possesses a gene resistant to Amp. As a result, only BL-21 (DE3) pLysS competent E. coli cells
carried the FGF-1 plasmid can survive. Agar plates were stored upside down and incubated
overnight (12-14 hours) at 37℃.
2. Protein Expression
a. Small-Scale Expression (SSE)
Small scale expression was carried out before large scale expression to examine the
presence of the protein of interest. It was conducted by inoculating one or more colonies from
the Agar plate into 10ml of LB broth containing 10µl Amp and incubated overnight (14-15
hours). The next morning, 5%/1 ml of the overnight culture was inoculated into 10mL of LB
containing 10µL of Amp and incubated at 37℃ for 2.15 hours at 250rpm. Optical density (OD)
of the culture was measured by UV visible spectrometer at wavelength 600 nm after 2.15 hours.
9µl IPTG was added to the culture as an inducer when it reached the required OD (between 0.6
to 0.8). The chemical structure of IPTG is analogous to allolactose. IPTG binds to and inactivates
the lac repressor. It leads to the activation of the lac operon and induction of protein expression
of BL-21 (DE3) pLysS competent E. coli cells. After 3.5 hours, the bacterial cells were
collected, sonicated, then centrifuged for 3 minutes at 13,000rpm to derive the protein of interest.
Four samples were applied in SDS-PAGE: uninduced (without IPTG addition), induced (IPTG
addition), pellet, and supernatant.
b. Trichloroacetic acid (TCA) Precipitation
TCA precipitation was conducted before SDS-PAGE. TCA is an acidic compound and
contains ester and salt. This procedure aims to obtain complete denatured protein due to the
disruption of non-covalent bonds such as the hydrogen-bonded water molecules surrounding a
protein and the addition of a reducing agent (2-mercaptoethanol) that can reduce disulfide bonds.
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A particular amount of TCA (10% of the protein volume) was added to the protein samples. The
mixture was vortexed and centrifuged at 13000rpm for 3 mins, and the supernatant was
discarded. 100% Acetone was added to wash the pellet and centrifugation was conducted again
at 13000 rpm for 3 min and the supernatant was discarded again. The pellets were air-dried. 8M
Urea was added to dissolve the pellets and 10μl loading dye was added into the dissolved pellet.
i.

Sodium-Dodecyl Sulfate-Polyacrylamide Agarose Gel Electrophoresis (SDS-PAGE)
The protein sample was applied in 15% Resolving gel and stacking gel. Composition of

the 15% resolving gel (2 gels) was 1.1ml ddH2O, 5ml 30% acrylamide, 3.75mL 1M Tris.HCl pH
8.8, 100 ul 10% SDS, 100 ul 10% APS, and 10 ul TEMED. While composition for the 15%
stacking gel (2 gels) was 3.75ml ddH2O, 0.83ml 30% acrylamide, 0.62mL 1M Tris.HCl pH 6.8,
50 ul 10% SDS, 50 ul 10% APS, and 10 ul TEMED. The gel was run at 200V, 100mA. Then, the
gel was stained by Coomassie Brilliant Blue for 3-5 min, rinsed with water, and put in the
destainer solution (contains methanol and acetic acid) overnight with KimWipes overlaid at the
top to absorb the dye. The gel was scanned the next day.
Large-Scale Expression (LSE)
Large quantities of hFGF-1 protein were generated through large-scale expression. The
procedure was the same as SSE, except 200ml of primary culture was inoculated, and 2 liters of
secondary culture was inoculated using 25ml of the inoculated and overnight incubated primary
culture. 50mg/ml ampicillin and 500μl of 1M IPTG were added. The 2 liters culture volumes
yielded two falcons tube containing 1liter pellets/each and was stored at -20℃.
Protein Purification
35ml of 10mM Phosphate Buffer (PB) pH 7.2 was used to dissolve the pellet obtained
from LSE. Ultrasonication was conducted to lyse the cells, and the lysate was separated from the
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cell debris by centrifugation at 19000 rpm for 25 min at 4℃. The supernatant was transferred to
a new falcon tube to be loaded onto the heparin sepharose column.
The column was pre-equilibrated with 2 column volumes (30ml) of 10mM PB pH 7.2.
The supernatant was then loaded onto the column. The flow-through/unbound protein was
collected if a peak was observed. Next, the peak was then base lined with 10mM PB pH 7.2.
Serial elution buffers containing 10mM PB and 100mM, 300mM, 500mM, 800mM, and
1500mM NaCl pH 7.2 were used in hFGF-1 protein purification. All the fractions were collected
and applied for TCA precipitation procedure before SDS-PAGE was run. hFGF-1 was eluted in
PB containing 1500mM NaCl. A thick band at ~16kDa verified the presence of pure hFGF-1
protein. The column was regenerated using 25ml 8M Urea, 50ml 10mM PB and 20ml 20%
ethanol. The column was stored at -20℃.
The pure hFGF-1 protein was concentrated by using a 10kDa concentrator in buffer
containing 25mM (NH4)2SO4, 100mM NaCl, and 10mM PBS. It was centrifuged at 4500rpm,
4℃ until reaching the desired volume. Then, concentrated hFGF-1 was stored at -80℃ for
further application in biophysical and biochemical characterizations.
3. Intrinsic Fluorescence Spectroscopy
The fluorescence emission spectrum of FGF-1 was conducted using Hitachi F-2500
spectrofluorometer at 25℃ (2.5nm resolution) and a quartz cell with a 1.0cm path length, in a
single beam mode. The samples for this experiment was prepared using 10μM FGF-1 in buffer
containing 100mM NaCl and 10mM PBS (pH 7.2); 0.01-10mM (0.2mM to induce fibril
formation); ratio of FGF-1 and SOS is 1:1-1:20. There are some sets of samples for this
experiment: FGF-1+SOS (1:1-1:20)+SDS (0.2mM); FGF-1+SDS (0.2mM)+SOS (1:1-1:20);
FGF-1+SOS (1:15)+SDS (0.01-10mM); and FGF-1+SOS (1:15)+ SDS (0.01-10mM). Each
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sample was triplicated, and incubation was performed at 37℃ for 6-7mins after the addition of
SOS and 10mins after the addition of SDS. The samples were excited at a wavelength of 280nm,
and the data was collected between 300nm and 450nm. Intrinsic fluorescence at these
wavelengths examined changes in tyrosine (308nm) and tryptophan (350nm) in FGF-1 when the
addition of SOS, SDS, the combination of SOS and SDS were performed. The aims of the
intrinsic fluorescence in this experiment were to assess alteration in the three-dimensional
structure and folding manner of FGF-1 when combined with SOS and SDS.
4) Extrinsic Fluorescence Spectroscopy
The fluorescence emission spectrum of FGF-1 was conducted using Hitachi F-2500
spectrofluorometer at 25℃ (2.5nm resolution) and a quartz cell with a 1.0cm path length, in a
single beam mode. The sample for this experiment was prepared using a protein concentration
of 10μM in buffer containing 100mM NaCl and 10mM PBS (pH 7.2), 0.01-10mM (0.2mM to
induce fibril formation); ratio of FGF-1 and SOS is (1:1)-(1:20), and 50mg/ml ThT (SigmaAldrich). There are some sets of samples for this experiment: FGF-1+SOS+SDS (0.2mM)+ThT;
FGF-1+SOS+SDS+ThT; FGF-1+SDS+SOS+ThT; FGF-1+SDS+SOS (1:15); and FGF1+SDS+ThT. Each sample was triplicated, and incubation was performed at 37℃ for 6-7mins
after the addition of SOS and 10mins after the addition of SDS. The samples were excited at a
wavelength of 440nm, and the data was collected between 455nm and 600nm. Fluorescence
intensity at 485nm was recorded.
5) Limited Trypsin Digestion
Both concentration and time-dependent limited trypsin digestion were conducted in
100mM NaCl and 10mM PBS (pH 7.2) with a total volume of 100μl. The concentration of trypsin
stock solution, FGF-1, SDS, and the ratio of FGF-1 and SOS were 3mg/ml; 10μM; 0.2mM;
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1:1,1:10,1:15, respectively. The concentration of trypsin used for the concentration-dependent
limited trypsin digestion was 0.02-0.5mg/ml (30mins incubation at 37℃) while the concentration
for the time-dependent, limited trypsin digestion was 0.04mg/ml. Some sets of samples were
applied for time-dependent limited trypsin digestion: FGF-1+trypsin; FGF-1+SDS+trypsin; FGF1+SOS(1:15)+trypsin;

FGF-1+SOS(1:1)+trypsin;

FGF-1+SOS(1:10)+trypsin;

FGF-

1+SDS+SOS(1:1); FGF-1+SDS+SOS(1:10); and FGF-1+SOS(1:15)+SDS. Each sample was
triplicated, and incubation was performed at 37℃ for 6-7mins after the addition of SOS and 10mins
after the addition of SDS. Pellet generated after incubation of FGF-1 and SDS were washed three
times with 100mM NaCl and 10mM PBS (pH 7.2) to remove excess SDS and centrifuged for 10
minutes at 13000 r.p.m. After the addition of trypsin, all the samples were incubated at 37℃ for
1-30mins. Next, all samples were subjected to TCA precipitation and applied for 15% SDS-PAGE.
Gels were stained using Coomassie Brilliant Blue (Sigma Aldrich) and analyzed using UN-SCAN
IT software densitometric by plotting the average pixel intensity versus time intervals.
6) Transmission Electron Microscope (TEM)
The samples for this experiment were prepared using 40μM FGF-1, 0.2mM SDS, and the
ratio of FGF-1, and SOS is 1:10 in the total volume of 100μl. There were five sets of samples
for this experiment: FGF-1; SDS; FGF-1+0.2Mm SDS; FGF-1+0.2mM SDS+SOS (1:10); FGF1+SOS(1:10)+0.2mM SDS. All samples were incubated at 37℃ for 24 hours. Pellets generated
after incubation with SDS were washed with ddH2O and dissolved with 40μl ddH2O. 10μl of
each sample were pipetted and applied in a separate grid. The samples were air-dried and stored
inside the petri dish. The morphology and size of the aggregates were investigated by highresolution Transmission electron microscopy (Jeol-HRTEM-2011, USA) with an accelerating
voltage of 80–100 kV. TEM images were taken at different magnifications.
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7) Mass Spectrometry
There were seven samples that are subjected to mass spectrometry: FGF-1+trypsin; FGF1+SOS (1:1); FGF-1+0.2mM SDS+trypsin; FGF-1+0.2mM SDS+SOS (1:1)+trypsin; FGF1+SOS (1:1)+0.2mM SDS+trypsin; FGF-1+SOS (1:10)+0.2mM SDS+trypsin; trypsin. The
concentration of FGF-1 and trypsin that were used in this experiment are 10μM and 0.04 mg/mL,
respectively. After trypsin addition, all samples were incubated at 37℃ for 30 minutes. 10μL of
TCA was added to each sample that contains trypsin and centrifuged for 3 minutes at 13.000
rpm. The supernatant of each sample was transferred to the new Eppendorf tubes. All samples
were sent to mass spectrometry facility in Poultry Science.

38

CHAPTER 3
RESULTS
The predominant native structure of FGF-1 is β-sheet that contains eight tyrosine, a
single tryptophan residue quenched in the native state, and three buried reduced cysteine
residues61,75, 76. Positive charges from the nearby histidine and lysine residues quench the
fluorescence of the single tryptophan at position 121 in hFGF-18, 77, 78. This quenching effect
corresponds to the presence of imidazole and pyrrole groups in the vicinity of the indole ring of
the tryptophan79. In native FGF-1, seven of eight tyrosine residues are exposed to the solvent,
whereas the single tryptophan shows a partial solvent accessibility59-61. Consequently, the
fluorescence behavior of FGF-1 is defined by eight tyrosine residues80. In the native state, FGF-1
shows a prominent peak at 305nm, which corresponds to the emission of tyrosine residues. Upon
disruption to the protein structure, a substantial amount of tryptophan fluorescence is observed
because the positively charged residues moved away from the indole ring and relieved the
quenching effect75.
FGFs are heparin-binding protein 61. Upon binding with heparin, FGFs are unsusceptible
to denaturation by acid or heat and proteases such as thrombin, trypsin, plasmin, subtilisin, papain,
and thermolysin54, 63. Crystallographic studies have shown that interaction between a high negative
charge density HS with positively charged amino acids in the N-terminus (residue 18) and Cterminus region (residues 112-128) exist64, 65. Another crystal structure (PDB ID: 1E0O) shown
that the C-terminal region of FGF-1 is a dominant heparin-binding site. Seven residues of FGF-1:
K126, K127, N128, K132, R133, R136, and K142 promote heparin-binding in this crystal
structure64. This study also revealed that van der Waals has a significant contribution to the binding
of heparin and FGF-164.
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Structural Changes Induced by SDS
Eight tyrosine and one tryptophan comprise the primary sequence of FGF-1. Measuring the
intrinsic fluorescence of these aromatic residues can provide information regarding alteration in
the tertiary structure of the protein. In the native state, hFGF-1 shows a prominent peak at
305nm, which corresponds to the emission of tyrosine residues. Upon disruption to the protein
structure, a substantial amount of tryptophan fluorescence is observed because the positively
charged residues moved away from the indole ring and relieved the quenching effect75. This
observed fluorescence is attributed to an emission maximum at around 350 nm. As a result, the
ratio of the fluorescence intensity at 305nm and 350nm (I305/I350) can be used to monitor the
change in the tertiary structure of hFGF-1.
The fluorescence emission spectrum of hFGF-1 is dominated by a single peak near
305nm upon excitation at 280nm (orange line in figure 17), and the tryptophan fluorescence is
substantially quenched at pH 7.2 at 25℃. At 37℃, a red shift is observed because FGF-1 is in a
partially unfolded state with the peak around 310 nm. In the presence of 0.02-0.04mM SDS, blue
shift in λmax is observed relative to hFGF-1 only. The observed shift is from 310nm (hFGF-1 only
at 37℃) to around 305nm due to the hydrophobic environment but without any significant
change in fluorescence emission intensities. A drastic change of the λmax occurs at the
concentration of SDS from 0.08mM to 0.2mM relative to hFGF-1 only at 37℃, from 310nm to
around 325nm (bathochromic shift) (figure 17). The spectrum of hFGF-1 in the presence of
0.08mM-0.2mM shows significant broad shoulder at 350nm, which corresponds to the emission
of the previously quenched tryptophan residues. These changes are not found when hFGF-1
interacts with 0.02-0.04mM SDS due to a quenched tryptophan residue in the native state when
protein is still properly folded. At 0.2-0.6mM of SDS, fluorescence intensity is decreased with
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shift of λmax by ~10nm (from 325nm to around 315nm) (figure 17) and this region is attributed
for partial unfolding of tryptophan residue. This result indicates that perturbation occurs in the
tertiary structures of protein due to the presence of SDS in this concentration. hFGF-1 in the
presence of 1-10mM SDS results in the peak centered at ~314nm with a broad shoulder at
~340nm. It suggests that this range concentration of SDS induces a partial degree of the
unfolding of tryptophan residue in hFGF-1. A significant reduction of the ratio of 305nm to
350nm (I305/I350) (figure 16) is observed at 0.07mM-10mM SDS with the lowest point at 0.1mM
SDS and 0.2mM SDS (Figure 16). It indicates that at this range of concentration, the tertiary
structure of the hFGF-1 is significantly altered due to the alteration in the microenvironment of
the tryptophan residue. Whereas, a higher value of I305/I350 indicates a more native-like, properly
folded structure75.
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Figure 14 Intrinsic Fluorescence Analysis of hFGF-1 in the Presence of SDS
Fluorescence intensity ratio (I305/I350) as measured as a function of different concentration of
SDS in PB buffer in 100mM NaCl (pH 7.2) after 10 minutes of incubation 37℃.
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Spectra of hFGF-1 in the presence of SDS
3500

Fluorescence Intensity

3000
2500
2000
1500
1000
500
0
300

350
Wavelength (nm)

400

450

wtFGF1 @37°C
wtFGF1 @25°C
wtFGF1+SDS (0.01mM)
wtFGF1+SDS (0.02mM)
wtFGF1+SDS (0.03mM)
wtFGF1+SDS (0.04mM)
wtFGF1+SDS (0.05mM)
wtFGF1+SDS (0.06mM)
wtFGF1+SDS (0.07mM)
wtFGF1+SDS (0.08mM)
wtFGF1+SDS (0.09mM)
wtFGF1+SDS (0.1mM)
wtFGF1+SDS (0.2mM)
wtFGF1+SDS (0.3mM)
wtFGF1+SDS (0.4mM)
wtFGF1+SDS (0.5mM)
wtFGF1+SDS (0.6mM)
wtFGF1+SDS (0.7mM)
wtFGF1+SDS (0.8mM)
wtFGF1+SDS (0.9mM)
wtFGF1+SDS (1mM)
wtFGF1+SDS (2mM)
wtFGF1+SDS (3mM)
wtFGF1+SDS (4mM)
wtFGF1+SDS (5mM)
wtFGF1+SDS (6mM)
wtFGF1+SDS (7mM)
wtFGF1+SDS (8mM)
wtFGF1+SDS (9mM)
wtFGF1+SDS (10mM)

Figure 15 Intrinsic Fluorescence Spectra of hFGF-1 in the presence of SDS
Spectra of hFGF-1 in the presence of different concentration of SDS in PB buffer in 100mM
NaCl (pH 7.2) after 10 minutes of incubation at 37℃.
hFGF-1 is incubated together with different ratios of SOS to hFGF-1 and 0.2mM SDS to
observe the ability of SOS to protect the tertiary structure of the protein from SDS. A
Comparison of the spectrum of hFGF-1 in the presence of 0.2mM SDS and the spectra of hFGF1, different ratio of SOS to hFGF-1, and 0.2mM SDS shows a blue shift from ~317nm (hFGF-1
and 0.2mM SDS) to ~309nm (hFGF-1, 0.2mM SDS, different ratio of SOS to hFGF-1). The
spectra also show a reduction in the fluorescence intensity relative to the hFGF-1 in the presence
of 0.2mM SDS. The spectra of hFGF-1 in the presence of different ratios of SOS to hFGF-1 and
0.2mM SDS compare to hFGF-1 and 0.2mM SDS show diminished broad shoulders at 340nm.
The emission of quenched tryptophan residues in the nonpolar environment inside the protein
globule (in hFGF-1 and 0.2mM SDS tryptophan quenching is relieved) is attributable to this
event. The result of I305/I350 shows the highest value (around 5) at the ratio of hFGF-1 to SOS
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(1:10), (1:15), and (1:20) (Figure 17). It indicates a more native-like, properly folded structure of
the protein in the presence of SOS. Furthermore, this finding suggests that SOS binds first to
stabilize and protect native conformation of hFGF-1 so that SDS cannot perturb and induce
alteration in the tertiary structure of the protein.
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Spectra of hFGF-1+SOS+0.2mM SDS
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Figure 16 Intrinsic Fluorescence Spectra of hFGF-1+SOS+0.2mM SDS
Spectra of hFGF-1 in the presence of different ratio of hFGF-1 to SOS and 0.2mM SDS in PB
buffer in 100mM NaCl (pH 7.2) after 10 minutes of incubation at 37℃.
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Figure 17 Intrinsic Fluorescence of wtGF-1+SOS+0.2mM SDS
Fluorescence intensity ratio (I305/I350) measured as a function of different ratio of hFGF-1 to SOS
in PB buffer in 100mM NaCl (pH 7.2) after 10 minutes of incubation at 37℃. The error bars
show the standard deviation of triplicate samples.
The control samples, hFGF-1 at 25℃, 37℃, in the presence of SOS (1:1), and (1:10)
show peak at ~308 nm. Red shift (from~308nm to ~314nm) with the increase in fluorescence
intensity is observed in λmax when hFGF-1 is incubated with 0.2mM SDS and a different ratio of
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hFGF-1 to SOS relative to the control samples (figure 18). Another comparison of the spectrum
of hFGF-1 in the presence of 0.2mM SDS and hFGF-1 incubated with 0.2mM SDS and different
ratio of hFGF-1 to SOS, a blue shift is detected, from ~328nm to ~314nm. The broad shoulder
at 350nm with the lower fluorescence intensity compared to hFGF-1 in the presence of 0.2mM
SDS is also observed in these spectra. The decline of the broadness of the shoulder at 350 nm in
these spectra indicates that tryptophan residue is partially refolded to some extent from the
solvent-exposed region to the hydrophobic interior of the protein. This result is also confirmed
by the intrinsic fluorescence in which at the ratio of hFGF-1 to SOS (1:10), (1:15), (1:20), the
I305/I350 shows the highest value (around 2) (figure 19). Even though this value is less than the
I305/I350 of hFGF-1 only (about 5) but greater than the SDS-induced amyloid-like fibrils (hFGF-1
and 0.2mM SDS) (around 1), this finding indicates that the structural alteration occurred in the
fibrils in the presence of SOS that can cause a refolding process to some extent.
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Spectra of (hFGF-1+0.2mM SDS)+SOS
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Figure 18 Intrinsic Fluorescence Spectra of (hFGF-1+0.2mM SDS)+SOS
Spectra of hFGF-1 in the presence of different ratios of hFGF-1 to SOS and 0.2mM SDS in PB
buffer in 100mM NaCl (pH 7.2) after 10 minutes of incubation at 37℃ then SOS is added and
incubated for 6-7 minutes. FSS is stand for a sample containing hFGF-1, different ratio of
hFGF-1 to SOS and 0.2mM SDS.*FSS is hFGF-1, 0.2mM SDS, and SOS.
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Figure 19 Intrinsic Fluorescence of (hFGF-1+0.2mM SDS) +SOS
Fluorescence intensity ratio (I305/I350) measured as a function of different ratios of hFGF-1 to
SOS in PB buffer in 100mM NaCl. The error bars show the standard deviation of triplicate
samples.
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SDS-induced Fibrils Formation in FGF-1
Thioflavin-T (ThT), a cationic benzothiazole dye, is used as a fluorescent probe to
monitor the formation and growth of amyloid fibrils. It can be used to quantify fibrillation
through enhancement of emission intensity at 485nm by several orders of magnitude upon
binding to the linear arrangement of β-sheets of the amyloid fibrils74. When the compound
specifically binds to the highly ordered β-sheet structure of amyloid fibrils, the fluorescence
intensity of ThT increases significantly81.
Figure 20 showed that the relative fluorescence intensity at 485nm increases from
0.05mM and significantly exhibiting maximum intensity at 0.2mM with 40-fold increased
fluorescence intensity compared to the sample containing hFGF-1 only. Furthermore, the
spectrum of hFGF-1 in the presence of 0.2mM SDS shows the highest fluorescence intensity
(green line in figure 21). When the concentration of SDS increase (more than 0.2mM), a
decrease in fluorescence intensities are observed (0.3mM-3mM). In particular, the obvious
decrease in fluorescence intensity can be observed at 2-10mM of SDS. After the concentration of
SDS reached 3mM until 10mM, a plateau is observed in the fluorescence intensity. This result
exhibits that at a low concentration of SDS (below the CMC), the surface-accessible grooves
lined with aromatic amino acids or hydrophobic sides-chains are available for ThT binding as
protein exists as a partially structured state. In addition, below the CMC, SDS can form an
amyloid-like fibril structure in hFGF-1 in which ThT will specifically bind. Whereas, with
increasing concentrations of SDS (above the CMC) due to conformational changes of protein,
less amyloid-like fibrils structure, ThT intensity is decreased (Unpublished work by Dr. Sanhita
Maity and Zeina Al Raawi in Kumar group). We can derive a conclusion that 0.2mM SDS is the
concentration inducing amyloid fibril-like structure in hFGF-1. Result obtained from intrinsic
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fluorescence also confirms this finding that 0.2mM of SDS cause the most significant alteration
in the tertiary structure of the hFGF-1.
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Figure 20 ThT-related growth curves of hFGF-1 in the presence of SDS
ThT-related growth curves of hFGF-1 in the presence of a different concentration of SDS (010mM) in 10 mM PB buffer containing 100mM NaCl (pH 7.2) at 485nm.
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Figure 21 ThT Spectra of hFGF-1 in the presence of SDS
Spectra with the highest fluorescence intensity is shown in green. This spectrum is referred to
the sample containing hFGF-1 and 0.2mM SDS. The highest intensity of the ThT spectra in
sample containing hFGF-1 and 0.2mM SDS shows that this sample contains the highest
magnitude of fibrillation.
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In the presence of different ratios of hFGF-1 to SOS and SDS, we conduct two separate
ThT assay to quantify amyloid-like fibril formation. In the first experiment, the addition of
hFGF-1, SOS, 0.2mM SDS is done in simultaneous manner. Extrinsic fluorescence shows that
the decrease in the fluorescence intensity at 485nm as the ratio of protein to SOS increase (figure
22). The significant reduction of fluorescence intensity is shown at a ratio of hFGF-1 to SOS at
(1:10), (1:15), and (1:20). It indicates fewer fibrils are formed in these samples (less ThT
binding) and SOS can protect the tertiary structure of the protein from the perturbation of SDS
compare to the sample containing hFGF-1 and 0.2mM SDS only. Furthermore, it is found that
the ratio of hFGF-1 to SOS (1:1) is the least effective in decreasing amyloid-like fibrils in hFGF1.
While in the second experiment, hFGF-1 and 0.2mM SDS are first incubated for 10
minutes to allow amyloid-like fibril formation, then SOS is added, then incubation for the 6-7
minutes. ThT binding assay shows that in the presence of SOS, the fluorescence intensity at
485nm decrease as the ratio of hFGF-1 to SOS increase (figure 24). This decrease is related to
the reduction of the formation of the fibrils. The significant decrease is observed at the ratio
between hFGF-1 to SOS (1:15) and (1:20) relative to the sample in the absence of SOS. It
suggests that SOS can reduce the formation of the amyloid-like fibrils in hFGF-1. The result
from the intrinsic and ThT extrinsic fluorescence indicates that SOS can protect the tertiary
structure of the hFGF-1 from the perturbation of 0.2mM SDS and reduced the fibril formation.
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Figure 22 ThT Spectra of hFGF-1+SOS+0.2mM SDS
Spectra with the highest fluorescence intensity is shown in orange. This spectrum is referred to
the sample containing hFGF-1 and 0.2mM SDS. As the concentration of SOS increases, the
fluorescence intensity decreases. It indicates less fibrils bind to the ThT.
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Figure 23 ThT-related growth curves of hFGF-1 in the presence of SOS and 0.2mM SDS
ThT-related growth curves of hFGF-1 in the presence of a different ratio of hFGF-1 to SOS and
0.2mM SDS in 10 mM PB buffer containing 100mM NaCl (pH 7.2) at 485nm.
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Figure 24 ThT Spectra of (hFGF-1+ 0.2mM SDS)+SOS
Spectra with the highest fluorescence intensity is shown in orange. This spectrum is referred to
the sample containing hFGF-1 and 0.2mM SDS. As the concentration of SOS increases, the
fluorescence intensity decreases. It indicates less fibrils binds to ThT
.
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Figure 25 ThT-related growth curves of hFGF-1 in the presence of 0.2mM SDS and SOS
ThT-related growth curves of hFGF-1 in the presence of a different ratio of hFGF-1 to SOS and
0.2mM SDS in 10 mM PB buffer containing 100mM NaCl (pH 7.2) at 485nm.
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Structure of SDS-induced Fibrils Formation in FGF-1
The morphological changes of 0.2mM SDS-induced amyloid-like fibril in hFGF-1 in the
presence of SOS is examined by transmission electron microscope (TEM). TEM result in figure
33 (a) depicts the individual spherical-like aggregates which formed upon incubation of merely
hFGF-1 for 24 hours at 37℃ in buffer containing 100mM NaCl in 10 mM phosphate buffer (pH
7.2). In the presence of 0.2mM SDS (figure 33 (b)), aggregates showed thicker, longer, fibrillar
assemblies.
When hFGF-1 is incubated with 0.2mM SDS and hFGF-1:SOS (1:10) for 24 hours at
37℃ (Figure 33 (c)), the thick fibrillar assemblies are disaggregated, shown by a significant
decrease in the length and density of the fibrillar assemblies. This data indicates that SOS could
destabilize the fibrillar assemblies of hFGF-1 induced by 0.2mM SDS. Incubation of hFGF-1
with hFGF-1:SOS (1:10) and 0.2mM SDS (figure 33 (d)) shows spherical-like aggregates (the
same structure was also observed in the incubation of hFGF-1 only in figure 33 (a)), less dense,
and branched aggregates compare with hFGF-1 in the presence of 0.2mM SDS only. It can be
suggested that the addition of SOS before 0.2mM SDS can prevent the formation of fibrillar
assemblies of hFGF-1. SOS is capable of binding and stabilizing FGFs. Upon binding to SOS,
FGFs are protected against high temperatures and low pH11. SOS binds to a positively charged
region of FGF-1. This region contains residues 112-127 where SOS mainly interacts with
Lys112, Arg116, Lys118, and Arg122 (heparin-binding site). Binding of SOS and FGF-1 allows
the neutralization of several positively charged residues that can destabilize the native structure
of FGF-1 by electrostatic repulsion67. Stabilization of hFGF-1 by SOS presumably protects
hFGF-1 from the denaturant activity of SDS at a certain level.
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(a)

(b)

(c)

(d)

Figure 26 TEM Images
(a) hFGF-1; (b) hFGF-1 in the presence of 0.2mM SDS; (c) hFGF-1 in the presence of 0.2mM
SDS and SOS (1:10); (d) hFGF-1 in the presence of SOS (1:10) and 0.2mM SDS. The reaction
mixture containing 40 μM hFGF-1, hFGF-1:SOS (1:10), 0.2mM SDS, and 100 mM NaCl in 10mM
phosphate buffer (pH 7.2), incubation at 37℃ for 24 hours.
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The Flexibility of the Backbone of FGF-1 is Diminished in SDS-induced Fibrils
Formation in FGF-1
Limited proteolytic digestion has been applied to map surface-exposed, flexible, or
weakly structured areas of folded, globular, monomeric, and oligomeric proteins, and to
assess protein folding dynamics82. This technique is based on the proteolytic digestion that is
governed by the presence of an appropriate protease recognition sequence in the protein
substrate, the availability of that sequence for cleavage, and the specificity of the proteolytic
enzyme82, 83. In this study, limited proteolysis experiment was performed to assess the stability of
SDS-induced amyloid-like fibrils towards proteolytic degradation. Trypsin was used in this
experiment because hFGF-1 contains many lysine and arginine residues (a constituent of the
putative heparin binding site) in its sequence, and most of them are concentrated in the Cterminal segment (residues 105-140)83.
We carried out concentration-dependent trypsin digestion to find out the concentration of
trypsin in which 80% of the hFGF-1 will be digested in 30 minutes incubation. Figure 27 depicts
the result of the SDS-PAGE of concentration-dependent limited trypsin digestion of hFGF-1 and
figure 28 shows the result of the densitometric analysis. We applied 0.04mg/mL (around 95% of
the protein is digested) of trypsin for the time-dependent limited trypsin digestion for the hFGF-1
only, hFGF-1 in the presence of 0.2mM SDS, hFGF-1 in the presence of SOS, and hFGF-1 in the
presence of both 0.2mM SDS and SOS. This trypsin concentration was chosen because it gave
the highest percentage of undigested protein compare to the other concentration; even though it
did not reach 80% of undigested protein in 30 minutes of incubation (figure 28). We carried out
time-dependent limited trypsin digestion of hFGF-1 only with the concentration of trypsin
0.04mg/mL. This sample acts as a control that the densitometric analysis will be compared with
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hFGF-1 in the presence of 0.2mM SDS, different ratio of hFGF-1 to SOS, and a combination of
0.2mM SDS and different ratio of hFGF-1 to SOS. Both the result of the SDS-PAGE and the
densitometric analysis in (figure 29 and 30) show that in 5-10 minutes almost all of the protein is
digested.
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Figure 27 The SDS-PAGE analysis of hFGF-1 concentrationdependent limited trypsin digestion.
Lane 1: hFGF-1 only. Lane 2: hFGF-1+0.02mg/mL trypsin. Lane 3:
hFGF-1+0.04mg/mL trypsin. Lane 4: hFGF-1+0.06mg/mL trypsin. Lane
5: hFGF-1+0.08 mg/mL trypsin. Lane 6: hFGF-1+0.1 mg/mL trypsin.
Lane 7: hFGF-1+0.2 mg/mL trypsin. Lane 8: hFGF-1+0.4 mg/mL
trypsin. Lane 9: hFGF-1+0.5 mg/mL trypsin. Lane 10: trypsin only. All
samples are incubated for 30 minutes.
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Figure 28 Densitometric analysis of concentrationdependent limited trypsin digestion of hFGF-1
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Figure 29 The SDS-PAGE analysis of hFGF-1 time-dependent
limited trypsin digestion (0.04mg/mL).
All samples contain hFGF-1 and trypsin 0.04 mg/mL. Lane 1: hFGF-1
only. Lane 2: 1 minute incubation. Lane 3: 2 minutes incubation. Lane 4:
4 minutes incubation. Lane 5: 5 minutes incubation. Lane 6: 6 minutes
incubation. Lane 7: 8 minutes incubation. Lane 8: 10 minutes incubation.
Lane 9: hFGF-1. Lane 10: 12 minutes incubation. Lane 11: 15 minutes
incubation. Lane 12: 18 minutes incubation. Lane 13: 21 minutes
incubation. Lane 14: 24 minutes incubation. Lane 15: 27 minutes
incubation. Lane 16: 30 minutes incubation

Average Percentage of Undigested Protein

Time-Dependent Limited Trypsin Digestion
of hFGF-1 (Trypsin 0.04mg/mL)
100
90
80
70
60
50
40
30
20
10
0
0 1 2 4 5 6 8 10 12 15 18 21 24 27 30
Time of Incubation (mins)

Figure 18 Densitometric analysis of time-dependent
limited trypsin digestion of hFGF-1
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SDS-PAGE result from the trypsin digestion of SDS-induced amyloid-like fibrils in
hFGF-1 (figure 31) showed that SDS-induced fibrils are not totally digested after 30 minutes of
incubation (figure 31). It is also observed that trypsin digestion is slower in SDS-induced
amyloid-like fibrils (figure 32) compared to the digestion of native hFGF-1. This result shows
that SDS-induced amyloid-like fibrils in hFGF-1 are resistant to proteolytic degradation, one of
the peculiar characteristics of amyloid fibrils84. In the presence of different ratios of hFGF-1 to
SOS (1:1 and 1:10), the SDS-PAGE results show that hFGF-1 is resistant to proteolytic
degradation where the bands of the hFGF-1 are still intact until 30 minutes of incubation with
trypsin (figure 33 and 35). The densitometric analysis shows that in the presence of SOS (1:10)
(figure 36), the degree of insusceptibility of hFGF-1 to the proteolytic degradation increase in
which around 20% of the protein is digested. Whereas, approximately 40% of the protein is
digested in the presence of SOS (1:1) (figure 34). Upon binding of SOS, hFGF-1 is stabilized by
the elimination of electrostatic repulsion so that it is resistant towards proteolytic degradation.
Moreover, it indicates that upon binding of SOS, hFGF-1 is less dynamic/mobile; in many cases,
limited proteolysis was observed to take place at sites of the polypeptide chain exhibiting high
segmental mobility84.
In the presence of SOS (1:1 and 1:10), SDS-induced amyloid-like fibrils in hFGF-1 are
resistant to proteolytic degradation shown by the SDS-PAGE result in which the bands are still
intact until 30 minutes of incubation with trypsin (figure 37 and figure 39). The densitometric
analysis shows that SDS- induced fibril is digested to around 70% after exposure to SOS (1:1)
(figure 38). While, after exposure to SOS (1:10), densitometric analysis (figure 40) shows that
SDS- induced fibril is digested to approximately 80%.
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Figure 31 The SDS-PAGE analysis of time-dependent limited
trypsin digestion of hFGF-1, SDS 0.2mM, and trypsin
0.04mg/mL.
All samples contain hFGF-1, 0.2mM SDS, and 0.04mg/mL trypsin.
Lane 1: hFGF-1+0.2mM SDS (0 minute). Lane 2: 1 minute
incubation. Lane 3: 2 minutes incubation. Lane 4: 4 minutes
incubation. Lane 5: 5 minutes incubation. Lane 6: 6 minutes
incubation. Lane 7: 8 minutes incubation. Lane 8: 10 minutes
incubation. Lane 9: 12 minutes incubation. Lane 10: 15 minutes
incubation. Lane 11: 18 minutes incubation. Lane 12: 21 minutes
incubation. Lane 13: 24 minutes incubation. Lane 14: 27 minutes
incubation. Lane 15: 30 minutes incubation.
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Figure 32 Densitometric analysis of time-dependent
limited trypsin digestion of hFGF-1, SDS 0.2mM, and
trypsin 0.04mg/mL.
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Figure 33 The SDS-PAGE analysis of time-dependent limited
trypsin digestion of hFGF-1, hFGF-1:SOS (1:1), and
0.04mg/mL trypsin.
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limited trypsin digestion of hFGF-1, hFGF-1:SOS (1:1),
and trypsin 0.04mg/mL.
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Figure 35 The SDS-PAGE analysis of time-dependent limited
trypsin digestion hFGF-1, SOS (1:10), trypsin 0.04mg/mL.
All samples contain hFGF-1, hFGF-1:SOS (1:10), and trypsin
0.04mg/mL. Lane 1: hFGF-1+SOS (1:10). Lane 2: 1 minute
incubation. Lane 3: 2 minutes incubation. Lane 4: 4 minutes
incubation. Lane 5: 5 minutes incubation. Lane 6: 6 minutes
incubation. Lane 7: 8 minutes incubation. Lane 8: 10 minutes
incubation. Lane 9: hFGF-1+SOS (1:10). Lane 10: 12 minutes
incubation. Lane 11: 15 minutes incubation. Lane 12: 18 minutes
incubation. Lane 13: 21 minutes incubation. Lane 14: 24 minutes
incubation. Lane 15: 27 minutes incubation. Lane 16: 30 minutes
incubation.
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Figure 36 Densitometric analysis of time-dependent
limited trypsin digestion of hFGF-1, SOS (1:10), and
trypsin 0.04mg/mL.
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Average Percentage of Undigested Protein

Figure 37 The SDS-PAGE analysis of time-dependent limited
trypsin digestion hFGF-1, SDS 0.2mM, SOS (1:1), and trypsin
0.04mg/mL.
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(1:1), trypsin 0.04mg/mL.
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All samples contain hFGF-1, SDS 0.2mM, and hFGF-1:SOS (1:10),
and trypsin 0.04mg/mL. Lane 1: hFGF-1+SDS 0.2mM+SOS (1:10).
Lane 2: 1 minute incubation. Lane 3: 2 minutes incubation. Lane 4:
4 minutes incubation. Lane 5: 5 minutes incubation. Lane 6: 6
minutes incubation. Lane 7: 8 minutes incubation. Lane 8: 10
minutes incubation. Lane 9: 12 minutes incubation. Lane 10: 15
minutes incubation. Lane 11: 18 minutes incubation. Lane 12: 24
minutes incubation. Lane 13: 27 minutes incubation. Lane 14: 30
minutes incubation. Lane 15: 21 minutes incubation.
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Figure 39 The SDS-PAGE analysis of time-dependent limited
trypsin digestion of hFGF-1, SDS 0.2mM, SOS (1:10), and
trypsin 0.04mg/mL.
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Figure 40 Densitometric analysis of time-dependent
limited trypsin digestion of hFGF-1, SDS 0.2mM, SOS
(1:10), and trypsin 0.04 mg/mL
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When hFGF-1 was incubated for 6-7 minutes with SOS (1:15) and followed by the addition
of 0.2mM SDS with 10 minutes incubation, the densitometric analysis profile is almost the same
with the samples containing hFGF-1 and SOS (1:10) (figure 43). The same result was also found
in samples that contain SOS (1:15), 0.2mM SDS, and hFGF-1 (figure 44). It can be suggested that
this resistant property is due to the stabilization effect of the SOS that reduces the flexibility of
hFGF-1 so that SDS cannot access the protein and perturb its structure.
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Figure 41The SDS-PAGE analysis of hFGF-1 time100
dependent limited trypsin digestion of hFGF-1, SOS
80
(1:15), SDS 0.2mM, and trypsin 0.04mg/mL.
All samples contain hFGF-1, hFGF-1:SOS (1:10), and SDS
60
0.2mM, and trypsin 0.04mg/mL. Lane 1: hFGF-1+ SOS
(1:15)+SDS 0.2mM. Lane 2: 1 minute incubation. Lane 3: 2
40
minutes incubation. Lane 4: 4 minutes incubation. Lane 5: 5
20
minutes incubation. Lane 6: 6 minutes incubation. Lane 7: 8
minutes incubation. Lane 8: 10 minutes incubation. Lane 9:
0
hFGF-1+ SOS (1:15)+SDS 0.2mM. Lane 10: 12 minutes
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Time of incubation (mins)
incubation. Lane 11: 15 minutes incubation. Lane 12: 18
minutes incubation. Lane 13: 21 minutes incubation. Lane 14:
24 minutes incubation. Lane 15: 27 minutes incubation. Lane Figure 42 Densitometric analysis of time-dependent limited
trypsin digestion of hFGF-1, SOS (1:15), SDS 0.2mM SDS, and
16: 30 minutes incubation.
trypsin 0.04mg/mL
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Overall, these experiments show that hFGF-1 in the presence of 0.2mM SDS (SDSinduced amyloid-like fibrils) and SOS (in different order of addition) are resistant to proteolytic
degradation in different degree compare to native hFGF-1 (figure 45). If SOS can disrupt the
fibrils (green line in figure 45), fragments of the fibrils show more resistance to proteolytic
degradation compare to the SDS-induced amyloid-like fibrils itself (orange line in figure 45).
Since the profile of the densitometric analysis of a sample containing hFGF-1 and SOS (1:10) is
almost the same as the sample containing hFGF-1, SOS (1:15), and 0.2 mM SDS. It can be
suggested that SOS stabilizes the protein and reduce its mobility so that trypsin could not digest
the protein, and SDS could not fully perturb the structure of hFGF-1. Presumably, stabilization
of the heparin-binding pocket renders the ability of hFGF-1 to protect and reduce the chance of
amyloid fibrils formation induced by 0.2mM SDS.
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Figure 43 The SDS-PAGE analysis of hFGF-1 timedependent limited trypsin digestion of SOS (1:15), SDS
0.2mM, and hFGF-1.
All samples contain SOS (1:15), SDS 0.2mM, and hFGF1, and trypsin 0.04mg/mL. Lane 1: SOS (1:15)+ SDS
0.2mM+hFGF-1. Lane 2: 1 minute incubation. Lane 3: 2
minutes incubation. Lane 4: 4 minutes incubation. Lane 5:
5 minutes incubation. Lane 6: 6 minutes incubation. Lane
7: 8 minutes incubation. Lane 8: 10 minutes incubation.
Lane 9: 12 minutes incubation. Lane 10: 15 minutes
incubation. Lane 11: 18 minutes incubation. Lane 12: 21
minutes incubation. Lane 13: 24 minutes incubation. Lane
14: 27 minutes incubation. Lane 15: 30 minutes incubation.
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Figure 44 Densitometric analysis of hFGF-1 time-dependent
limited trypsin digestion of SOS (1:15), SDS 0.2mM, and trypsin
0.04mg/mL
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SDS Binding-site in FGF-1
The basic of the mass spectrometry (MS) is the conversion of the molecules to gaseous ions in
the ion source85. Then, separation is based on their mass-to-charge ratios (m/z) in the mass
analyzer85. MS has emerged as a highly sensitive technique for amyloid aggregation studies and
provides new and complementary insights into the onset of amyloid ﬁbrils, including oligomer
characterization, aggregation mechanism investigation, and inhibitor screening85. Nevertheless,
in general, mass spectrometric methods have a relatively low tolerance for salts, buffers, and
other sample impurities86. This obstacle is overcome by the one feature of matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)86. Its ability to detect
biomolecules in complex mixtures in the presence of large molar excesses of salts, buffers, and
other species is the feature of MALDI-TOF that makes it a promising technique for mass
spectrometric analysis of biological samples86.
We performed MALDI-TOF mass spectrometry to analyze the tryptic fragment of the
hFGF-1; SDS-induced amyloid-like fibrils in hFGF-1, and the presence of SOS; hFGF-1-SOS
complex in the presence of 0.2mM SDS. The concentration of trypsin was 0.04mg/mL, and after
the addition of trypsin, all samples were incubated for 30 minutes. Figure 46 and 47 show the
tryptic fragment of the hFGF-1 only and hFGF-1 in the presence of SDS 0.2mM after 30
minutes, respectively. A comparison of the tryptic fragment from the two samples demonstrates
that peptide fragment AILFLPLPVSSD with the m/z 1271.868 is missing in SDS-induced
amyloid-fibrils. This finding suggests that this fragment is resistant to trypsin digestion.
However, this tryptic fragment is not fused with other amino acid residues. This result is
confirmed by the time-dependent limited trypsin digestion in which SDS-induced amyloid-like
fibrils in hFGF-1 is resistant to proteolytic degradation.
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Table 1 Mass to charge ratio (m/z) of tryptic fragments
Theoritical

m/z of hFGF-1

m/z of hFGF-

m/z of hFGF-

m/z of hFGF-

cleavage of hFGF-

1+ SDS

1+SDS

1+SOS(1:1)+SDS

1 by trypsin

0.2mM

0.2mM+SOS(1:1)

0.2mM

(ExPASy)
1379.6

733.353

733.289

733.345

863.483

1414.54

863.513

863.513

863.505

991.618

2244.49

991.651

991.608

991.637

1143.693

3482.79

1143.792

1143.792

1143.715

1180.687

1510.62

1271.868

1180.668

1180.705

1379.839

611.7

1379.886

1379.820

1271.862

1510.910

1510.880

1379.873

1639.025

863.03

1180.720

635.74

1510.950

1639

1328.872

2244.381

888.98

1639.061

2244.357

1414.924

2515.484

2525.02

2244.424

2515.456

1510.979

3481.482

2515.550

3481.497

1534.037

3481.580

1639.062
2244.411
2515.525
3481.525
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Figure 46 MALDI-TOF Mass Spectrometry Analysis of hFGF-1

Figure 47 MALDI-TOF Mass Spectrometry Analysis of hFGF-1+SDS 0.2mM

Comparing the fragment of the fibrils to hFGF-1 in the presence of SDS 0.2mM and SOS
(1:1) shows that all of the fragments of the fibrils are found in hFGF-1 in the presence of SDS
0.2mM and SOS (1:1). But there are three fragments that exist only in hFGF-1 in the presence of
SDS 0.2mM and SOS (1:1), fragment with the m/z of 1271.862, 1328.872, and 1414.924.
Fragment with the m/z 1271.862 corresponds to the AILFLPLPVSSD, which also finds in
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hFGF-1 only. It suggests that SOS perturb the structure of the fibrils. Extrinsic, Intrinsic
fluorescence and TEM results confirm this finding. TEM result indicates that SOS could
destabilize the fibrillar assemblies of hFGF-1 induced by 0.2mM SDS. The extrinsic
fluorescence result demonstrates the decrease in the fluorescence intensity at 485nm in the
presence of SOS (decrease in aggregation). Moreover, intrinsic fluorescence shows that fibrils in
the presence of different ratios of protein to SOS have a higher value of I305/I350 compare in the
absence of SOS. This indicates an alteration in the structure of the fibrils.
All of the fragments found in the fibrils also exist in the hFGF-1, SOS (1:1), and SDS
0.2mM, except one fragment with the m/z 733.289 (also found in hFGF-1). This indicates that
this concentration is not optimum to protect the structure of the hFGF-1. The result from the
intrinsic and extrinsic fluorescence also supports this finding, in the presence of SOS (1:1) the
I305/I350 shows the lowest value and the fluorescence intensity at 485 nm shows the highest value
in comparison to other ratios of protein to SOS.
We could not get the signal for the sample containing SOS (1:10). Presumably, this ratio
of hFGF-1 to SOS protects the structure of the hFGF-1 so that trypsin could not access and
digest the protein. Intrinsic fluorescence shows that SOS (1:10) shows the higher value of
I305/I350 compare to the presence of SOS in a lower ratio. At the same time, the result of extrinsic
fluorescence shows a significant decrease of fluorescence intensity at 485 nm in the presence of
SOS (1:10).
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Figure 48 MALDI-TOF Mass Spectrometry Analysis of hFGF-1+0.2mM SDS+SOS (1:1)

Figure 49 MALDI-TOF Mass Spectrometry Analysis of hFGF-1+SOS (1:1)+SDS 0.2mM

DISCUSSION
FGF-1 is known for its low stability and short half-life in vivo87. Almost 50% of the
protein is in the unfolded state at physiological temperature. The unfolded state of the FGF-1 is
known to be more susceptible to protease action87-89. SDS, an anionic detergent, resembles some
characteristics of biological membranes and a good representation of anionic phospholipids90.
The use of SDS as a fibrillar inducer is related to some reports in which lipid molecules
presumably played roles in the conformational change of various amyloid precursor protein and
the amyloid fibril formation in-vitro91-93. Electrostatic and hydrophobic interactions between
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SDS and a protein can trigger protein conformational changes, both their secondary and tertiary
structure94.
Moreover, SDS triggers the formation of aggregates or amyloid-like fibrils in vitro in
some proteins or peptides95, 96. Several investigations were attributed to the effect of SDS on
protein amyloid aggregation, with two contrary effects, inhibition, or enhancer of amyloid
formation; these effects are concentration dependent90, 97-99. The perturbation of protein structure
by SDS involves two primary and distinct events, tertiary structure unfolding in the sub micellar
and chain expansion in the micellar range of SDS concentrations100. The CMC for SDS is 7-8
mM in water but around 0.8-1 mM I PBS buffer97. Above its critical micelle concentration
(CMC), SDS has been known to stabilize peptides in helical conformations101, 102, whereas,
below its CMC, SDS has been shown to stabilize β-strands103, 104.
Pertinhez and coworkers (2002) reported that a high concentration of SDS (20mM)
causes the formation of a stable α-helical structure of SCR3 peptide that does not convert into
amyloid fibrils over the time of the investigation. Whereas, in the presence of sub-micellar
(3mM) SDS, a large quantity of fibrillar structures was observed96. Another study, concentration
of SDS above 1mM (above CMC) is found to increase α-helix content of β2-microglobulin (β2m) to around 10%, while reducing β-sheet content to approximately 20%90. A structural
investigation of the SDS-induced fibrillation of α-synuclein (αSN) showed that SDS at
concentration 1.2-3mM could not form aggregation; it is found that SDS at a concentration of
0.3-1.2mM generated optimum aggregation at dip 1 (highest enthalpic changes associated with
SDS binding)97. It is also found that the SDS molecules possess great potential to induce amyloid
formation in twenty-five proteins including lysozyme and human serum albumin. This ability is
observed when protein is in partially unfolded states (below two units of pI)105.
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In another study, thermally induced amyloid formation are found in Notopthalmus
viridescens FGF-1 (nFGF-1). Maximum fibril formation is observed at 65℃. Thermal induced
fibrils of nFGF-1 possess a typical “cross-β” structure with the β-strands perpendicular to the
fibril axis. The coalescence of the protein (in the intermediate state (s)) through the solventexposed non-polar surface(s) is the mechanism behind the fibril formation106.
The combined results of fluorescence spectroscopy, limited trypsin digestion,
transmission electron microscope (TEM), and mass spectrometry suggest that 0.2mM is the
optimum concentration of SDS to induce amyloid-like fibrils formation in hFGF-1. The presence
of SOS in the fibrillar structure of hFGF-1 induced by the SDS cause disaggregation of the
fibrillar structure. Furthermore, SOS seems to protect the structure of hFGF-1 so that trypsin
cannot digest the protein, and SDS cannot perturb the tertiary structure of the protein. Upon
binding to SOS, FGFs are protected against high temperatures and low pH11. SOS binds to a
positively charged region of FGF-1. This region contains residues 112-127 where SOS mainly
interacts with Lys112, Arg116, Lys118, and Arg122 (heparin-binding site). Binding of SOS and
FGF-1 allows the neutralization of several positively charged residues that can destabilize the
native structure of FGF-1 by electrostatic repulsion67. Stabilization of hFGF-1 by SOS
presumably protects hFGF-1 from the denaturant activity of SDS at a certain level.
Stabilization of the heparin-binding pocket renders the ability of hFGF-1 to protect
hFGF-1 and reduce the chance of amyloid fibrils formation. It has been known that under
physiological conditions, proteins present in equilibrium between ensembles of unfolded states
(U) and native states (N)107. Results obtained from this research suggest that the molecular
mechanism in which SOS can protect and reduce the chance of fibrils formation is presumably
through the stabilization of the native states of the hFGF-1 and also refolding unfolded states of
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the protein at particular degree. SOS seems to push the equilibrium to the more native, folded
state of the protein in the presence of 0.2mM SDS.
Refold unfolding states
SDS

Unfolding +
Native States

Reduce Fibrils formation
in hFGF-1

SOS

Stabilization of native states

Figure 50 Molecular Mechanism of SOS in Protecting and Reducing Fibrils Formation in
hFGF-1
Some previous studies link the presence of high levels of FGF-1 and the occurrence of
Alzheimer's disease. The first study observed that astrocytes containing high levels of FGF-1
presented around senile plaques in seven Alzheimer's patients' postmortem brain tissue6. The
examination was conducted by immunohistochemistry employing a specific antiserum against
FGF-16. The diagnosis of Alzheimer's disease was established in every case by the presence of a
large amount of plaques and tangles6. Plaques were presumed due to the high binding affinity
between FGF-1 and heparan sulfate proteoglycan6. This presumption is strengthened by the fact
that the mitogenic activity of FGF-1 is increased more than 100-fold by heparin and heparin
sulfate6.
The result from in vivo observation showed that high levels of secreted FGF-1 upregulated
apolipoprotein E (apoE) production in astrocytes of the brain injury lesion by autocrine
mechanism9. Therefore, it was presumed that stress conditions (e.g., heat shock, oxidation, and
long-term culture) trigger astrocytes to generate FGF-1 to induce the production of apoE-HDL
(apolipoprotein E-high-density lipoproteins), an important compound for the healing process in
the postinjury brain9. ApoE synthesis is triggered by FGF-1 via the PI3K/Akt (phosphoinositide
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3-kinases/ protein kinase B) pathway rather than Ras/MEK/Erk (mitogen-activated protein kinase/
extracellular signal-regulated kinase) pathway 9.
Another study found that the level of FGF-1 in the cerebrospinal fluid and serum of thirtytwo Alzheimer's patients were higher than those thirty-two patients without Alzheimer's disease
(normal controls)5. Western blotting and enzyme-linked immunosorbent assay (ELISA) was
carried out to measure the level of the FGF-15. This study was based on the fact that FGF-1 is one
of the most pivotal central nervous system (CNS) growth factors and a powerful mitogen5.
Moreover, it was assumed that biochemical brain abnormalities could be manifested in
cerebrospinal fluid (CSF) because of CSF proximity to the extracellular space of the brain 5. It was
found that FGF-1 plays an essential role in enhancing microglial and astrocyte-mediated
neuroinflammation10. Neuroinflammation, the hallmark of Alzheimer's disease progression, can
be a potential drug target in Alzheimer's drug development10. It can be pursued by blocking the
expression and release of FGF-1 because inhibition of FGF-1 can prevent the expression of
neuroinflammatory molecules10.
It is imperative to conduct further research to unravel the roles of FGF-1 in AD, focusing
on its potency to form amyloid-β confirmation to gain a detailed understanding of the
pathological mechanism of the disease. A previous study indicates that FGF-1 plays a certain
role in AD that can be a potential target therapy. Conducting in-vitro studies by using SDS as an
amyloid fibril inducer of FGF-1 can be a preliminary step to understanding the significant role of
FGF-1 in the pathophysiology of AD through the amyloid fibrils formation. Further development
of in vitro studies into in vivo studies will broaden understandings towards this topic.
Presumably, being able to simulate this process both in vitro and in vivo can aid future research
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in exploring a new avenue of Alzheimer’s drug development due to the nature of AD as a
multifactorial neurodegenerative disorder.
CONCLUSIONS
The combined results of fluorescence spectroscopy, limited trypsin digestion,
transmission electron microscope (TEM), and mass spectrometry from this study suggest that
0.2mM is the optimum concentration of SDS to induce amyloid-like fibrils formation in hFGF-1.
The presence of SOS is found to protect hFGF-1 from fibrillation induced by SDS, reduce, and
disaggregate fibrils formation in hFGF-1. Stabilization of the heparin-binding pocket renders the
ability of hFGF-1 to protect and reduce the chance of amyloid fibrils formation induced by
0.2mM SDS.
FUTURE PERSPECTIVE
Based on the result of this research, we can develop a future study to engineer the
heparin-binding pocket of hFGF-1 and comparing its stability. We found that in vitro condition,
0.2mM SDS can induce fibrils formation in hFGF-1. Moreover, we can examine the tendency of
the hFGF-1 to form fibrils in physiological conditions by using lipid vesicle, designing
molecules that have similar effects to SOS in stabilizing hFGF-1, and examining the toxicity of
FGF-1 fibrils in the animal model.
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